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Summary 
 
The mycotoxin ochratoxin A (OTA) exhibits a wide range of toxic effects in animals and 
humans including hepato-, nephro-, neuro-, and genotoxicity. The toxicity mechanisms of 
OTA are not yet fully understood. It has been suggested that inhibition of protein synthesis, 
disturbance of mitochondrial function, and oxidative stress are involved in OTA mediated 
toxicity. 
The studies presented in this thesis aimed to counteract OTA cytotoxicity in HepG2 cells by 
various antioxidants such as vitamin E and dietary flavonoids, for example epigallocatechin 
gallate and quercetin. Furthermore, the effects of N-acetylcysteine (NAC) and buthionine 
sulfoximine (BSO), modulators of intracellular glutathione (GSH) levels, on OTA cytotoxicity 
were investigated. 
Neither vitamin E nor flavonoids protected HepG2 cells from OTA induced cell death. This 
lack of protection by antioxidants might be due to an insufficient access of the antioxidants to 
the intracellular sites of reactive oxygen species (ROS) production and/or suggests a minor 
role for ROS in OTA mediated hepatotoxicity. In agreement, neither NAC nor BSO affected 
OTA induced cytotoxicity, suggesting that GSH may not be pivotally involved in the 
protection from acute OTA toxicity in HepG2 cells.  
A second aim of this thesis was to study the gene modulatory activity of OTA in HepG2 cells 
using Affymetrix GeneChip® technology. OTA reduced mRNA levels of genes encoding for 
proteins that are centrally involved in energy metabolism, such as phosphoglycerate kinase 
1, isocitrate dehydrogenase 3 (NAD+) beta, and uncoupling protein 2. All mitochondrial 
genes affected by OTA were at least twofold down regulated. A particularly strong down-
regulation was observed for mRNA and protein levels of the insulin-like growth factor binding 
protein 1, which has been demonstrated to counteract p53 mediated apoptosis in 
mitochondria. Overall, the data presented in this thesis suggest that OTA may mediate its 
cytotoxicity in liver cells partly by lowering mRNA levels of genes crucial for energy 
homeostasis.  
 II 
 
 
Zusammenfassung 
 
Das Mykotoxin Ochratoxin A (OTA), das vor allem Getreide kontaminiert, wirkt auf vielfältige 
Weise giftig für Mensch und Tier: OTA ist unter anderem leber-, nieren-, neuro-, und 
genotoxisch. Die Toxizitätsmechanismen von OTA sind bis heute nicht vollständig geklärt. Es 
wird vermutet, dass eine Hemmung der Proteinsynthese, eine Funktionsstörung der 
Mitochondrien sowie oxidativer Stress zur Toxizität von OTA beitragen. 
Die experimentellen Studien, die in dieser Arbeit vorgestellt werden, hatten zum Ziel, der 
durch OTA induzierten Toxizität in HepG2 Leberzellen mit verschiedenen Antioxidantien wie 
beispielsweise Vitamin E und Flavonoiden, z.B. Epigallocatechingallat und Quercetin, 
entgegenzuwirken.  
Darüber hinaus wurden die Effekte von N-Acetylcystein (NAC) und Buthioninsulfoximin 
(BSO) auf intrazelluläre Glutathion-Gehalte und OTA induzierten Zelltod systematisch 
untersucht. Weder Vitamin E noch die untersuchten Flavonoide schützten HepG2 Zellen 
signifikant vor Zelltod durch OTA. Der fehlende Schutz durch Antioxidantien könnte durch 
eine möglicherweise eher untergeordnete Rolle reaktiver Sauerstoffspezies (ROS) in der 
durch OTA verursachten Lebertoxizität oder durch einen unzureichenden Zugang der 
Antioxidantien zu den für die ROS Produktion entscheidenden zellulären Bildungsorten sein. 
Außerdem beeinflussten weder NAC noch BSO den Grad der Viabilität der mit OTA 
behandelten Zellen, was darauf schließen lässt, dass GSH in der Leber nicht zentral in die 
akute Toxizität von OTA involviert ist.  
Ein weiterer Schwerpunkt dieser Arbeit bestand darin, mittels Genchip-Technologie die 
genregulatorische Aktivität von OTA in HepG2 Zellen zu untersuchen. Der vorherrschende 
Effekt von OTA war eine Erniedrigung von mRNA Spiegeln von Genen, die für 
Schlüsselproteine des Energiestoffwechsels kodieren, wie zum Beispiel 
Phosphoglyceratkinase 1, Isocitratdehydrogenase 3 (NAD+) beta und Uncoupling Protein 2. 
Alle untersuchten mitochondriellen Gene, die OTA beeinflusste, wurden mindestens 
zweifach in ihren Expressionswerten erniedrigt. Ein besonders starker Abfall des mRNA und 
Protein-Gehaltes wurde für das Insulin-like Growth Factor Binding Protein 1 beobachtet, für 
das gezeigt wurde, dass es die apoptotischen Effekte von p53 in Mitochondrien 
antagonisiert. Insgesamt deuten die Befunde dieser Arbeit darauf hin, dass die Zytotoxizität 
von OTA in Leberzellen, zumindest teilweise, durch eine Erniedrigung der mRNA Gehalte 
von Genen vermittelt werden wird, die für die zelluläre Energiegewinnung von essentieller 
Bedeutung sind. 
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Abbreviations 
 
AGE Advanced Glycation End-Product 
ATP Adenosine Triphosphate 
BAK BCL2-antagonist/killer 
BEN Balcan Endemic Nephropathy 
BHT Butylated Hydroxytoluene 
BME Bovine Mammary Epithelium 
BSO Buthionine Sulfoximine 
CAT Catechin 
CYP450 Cytochrome P450 
DAI Daidzein 
DNA Deoxyribonucleic acid 
DPPH 1,1-Diphenyl-2-picrylhydrazyl 
EC Epicatechin 
EGCG Epigallocatechin Gallate 
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GSH Glutathione 
GST Glutathione-S-Transferase 
GSTO Glutathione-S-Transferase omega 
IARC International Agency for Research on Cancer 
IDH3B Isocitrate Dehydrogenase 3 (NAD+) Beta 
IGFBP1 Insulin-like Growth Factor Binding Protein 1 
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NRF2 Nuclear Factor, Erythroid Derived 2, Like 2 
OTA Ochratoxin A 
PFK Phosphofructokinase 
PGK1 Phosphoglycerate Kinase 1 
P53 Protein 53 
 IV 
PPP3CB Protein Phosphatase 3 (Formerly 2B), Catalytic Subunit, Beta 
Isoform (Calcineurin A Beta) 
PTWI Provisional Tolerable Weekly Intake 
QUE Quercetin 
RNA Ribonucleic Acid  
mRNA Messenger Ribonucleic Acid 
ROS Reactive Oxygen Species 
ROSAC Rosmarinic Acid 
SCF Scientific Committee on Food 
SOD Superoxide Dismutase 
TEAC Trolox-Equivalent Antioxidant Capacity  
α-TOC-P α-Tocopherol Phosphate 
α-TTP α-Tocopherol Transfer Protein 
UCP2 Uncoupling Protein 2 
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General Introduction 
The ochratoxins belong to the mycotoxins which comprise a large group of secondary 
metabolites of fungi. To date, nearly 400 mycotoxins are known and generally catagorized 
into different groups based on their structural similarities. An overview of selected 
mycotoxins, their main producers, occurrence and toxicological effects, is given in Table 1. 
Ochratoxins, together with aflatoxins, fumonisins, trichothecenes, and zearalenones, belong 
to the most common types of mycotoxins that may cause severe health problems in both 
domestic animals and in humans. To date, three ochratoxins are known, namely ochratoxins 
A, B, and C (OTA, OTB, OTC), which chemically consist of a dihydroisocoumarin moiety 
linked to phenylalanine (Figure 1). The most toxic ochratoxin is OTA, which was first isolated 
in 1965 from Aspergillus ochraceus [1]. OTA is heat stable [2] and slowly cleared from the 
body [3]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Chemical structure of ochratoxins 
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 Table 1  Overview of selected mycotoxins 
 
 
Toxin Main Producers Main Occurrence Main Effects Reference 
Aflatoxins Aspergillus flavus, Aspergillus parasiticus 
peanuts, cereals, figs, 
milk (carry over) hepatotoxic, carcinogen 
 
[4] 
 
Alternariol Alternaria alternata, Alternaria solani 
fruits, vegetables, 
tabac, sorghum, nuts mutagene [5] 
 
Deoxynivalenol 
 
Fusarium culmorum, 
Fusarium graminearum cereals 
induces vomiting, 
possibly immuno-
supressive 
[6] 
Fumonisins Fusarium moniliforme, Fusarium proliferatum mainly maize 
possibly carcinogen, 
genotoxic in cultured 
cells 
[7] 
 
Ergot alkaloids 
 
Claviceps purpurea 
 
cereals 
 
„ergotism“:convulsions, 
nausea, and diarrhea 
[8] 
Ochratoxins Aspergillus ochraceus, Penicillium verrucosum 
 
cereals, maize, 
grapes, beans, nuts 
etc. 
 
nephro-, hepatotoxic, 
cancerogen, mutagen, 
immunosuppressive 
etc. 
[9] 
Patulin 
Penicillium claviforme 
Penicillium expansum 
Penicillium griseofulvum 
apples, other fruits 
haemorrhagic, 
oedematous, 
cancerogen (in animal 
studies) 
[10, 11] 
Trichothecene mainly Fusarium species, 
also Cephalosporium etc. cereals 
dermatotoxic, 
immunosuppressive, 
leading to nausea and 
diarrhea 
[12, 13] 
Zearalenon  various Fusarium species, cereals, nuts estrogenic, possibly leading to infertility [14] 
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OTA is produced by several Aspergillus and Penicilium species and mainly contaminates 
cereals [15, 16], but also legumes, oilseeds, grapes [17], beans, spices and dried fruits, to 
name a few [18]. Due to a carry over effect OTA can also occur in blood [19-21], meat [22] 
and milk [23]. 
 
Over the last decades numerous animal and cell culture studies showed that OTA exhibits a 
wide range of toxic effects: OTA has been associated with nephrotoxicity [24, 25], 
hepatotoxicity [26, 27] neurotoxicity [28], genotoxicity [29, 30], teratogenicity [31, 32], and 
immunosuppression [33, 34]. It has also been reported that OTA may cause cancer in rats 
[35], mice [36] and trout [37]. The fact that OTA toxicity differs strongly between species can 
partly be explained by the differences in half-lives of OTA and a species-specific metabolism 
[38]. Ruminants, for example, are relatively resistant to the acute toxic effects of OTA due to 
extensive degradation of OTA to its less toxic metabolite ochratoxin alpha by microorganisms 
in the rumen [39, 40]. In contrast, OTA is highly toxic in monogastric species such as 
rodents, poultry and pigs [9]. Oral LD50 values of OTA are 20 mg/kg for young rats and 3.6 
mg/kg for chickens [41]. Based on similarities to the OTA-induced porcine nephropathy [24], 
OTA has been linked to a severe human kidney disease called Balcan endemic nephropathy 
(BEN) [20]. Contrary, data of OTA intake and corresponding serum concentrations, as 
compared to data in laboratory rats, suggest that human OTA exposure might be too low to 
cause nephrotoxic lesions as observed in BEN [42]. Other studies underline the risks of 
possible chronic toxic effects of OTA; in this context it has been recently hypothesized that 
long-term exposure to low doses of OTA may even lead to an earlier onset of parkinsonism 
[43].  
The International Agency for Research on Cancer (IARC) has classified OTA as a putative 
human carcinogen [44]. The toxicity of OTA in food has been evaluated by the Joint Food 
and Agriculture Organization/World Health Organization Expert Committee on Food 
Additives (JECFA), and by the European Commission's Scientific Committee on Food (SCF) 
[45]. The JECFA established a provisional tolerable weekly intake (PTWI) of 100 ng/kg body 
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weight based on the Lowest Observed Effect Level (LOEL) for renal effects in pigs. The SCF 
recommended reducing OTA exposure as much as possible and preferably below a value of 
5 ng/kg body weight per day.  
While several mechanisms for OTA toxicity have been proposed, its precise mode of action 
is currently not fully understood. In the 1970’s, it was shown that OTA disturbs the 
mitochondrial respiration in isolated rat liver mitochondria [46] and reduced the enzyme 
activity of NADH-tetrazolium reductase and succinate dehydrogenase in tubular cells of pigs 
[47]. In the 1980’s, it was demonstrated that OTA inhibits protein biosynthesis by competition 
with phenylalanine in the phenylalanine-tRNA acylation reaction [48], and over the last two 
decades many studies also revealed an increase of reactive oxygen species (ROS) 
production and lipid peroxidation due to OTA [49-51]. It is well-known that ROS can damage 
lipids [52], proteins [53], and nucleic acids [54], thus possibly being a starting point of OTA 
induced toxicity. Therefore, one of the objectives of the present study was to test whether 
OTA toxicity can be counteracted by antioxidants such as vitamin E and polyphenols. 
Vitamin E was used, because it is the most important chain breaking lipid-soluble antioxidant 
in vivo [55]. However, also non-antioxidant properties of vitamin E including signal 
transduction and gene regulation, have been demonstrated over the last years [56].  
We have  shown in a preliminary experiment in HepG2 liver cells (Chapter two) that vitamin 
E did not affect mRNA levels of cytochrome P450 (CYP450) enzymes which are believed to 
be involved in OTA metabolism [57]. Thus vitamin E is not interfering with phase I enzymes 
and therefore may be a potential candidate for counteracting OTA induced cytotoxicity. 
Vitamin E is not a single substance but a generic term for a group of eight natural 
compounds, namely α-, β-,γ and δ- tocopherols and -tocotrienols [56, 58]. Of these eight 
isoforms, α-tocopherol exhibits the highest biological activity and is preferentially 
incorporated into lipoproteins and secreted into plasma facilitated by the α-tocopherol 
transfer protein (α-TTP) [59]. α-Tocopherol has been demonstrated to function as a potent 
inhibitor of lipid peroxidation by scavenging peroxyl radicals [60, 61]. Furthermore, there has 
been evidence for a 10% reduction in OTA induced cell mortality of bovine mammary 
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epithelium (BME-UV1) cells by α-tocopherol [62]. Therefore we have chosen α-tocopherol as 
a test substance which may antagonize OTA-induced oxidative stress in hepatocytes. 
Additionally, we tested several flavonoids for their potency to counteract OTA induced 
cytotoxicity in cultured HepG2 cells. Flavonoids are a large group of antioxidant polyphenols, 
that can be further divided into subclasses such as flavones, isoflavones, flavanols 
(catechins), flavonols, flavanones, anthocyanins, and proanthocyanidins [63]. We used 
catechin (CAT), epicatechin (EC), and epigallocatechin gallate (EGCG) since they have been 
described as inhibitors of radical reactions in human plasma [64]. Furthermore, the 
isoflavones genistein (GEN), daidzein (DAI) and equol (EQU) have been shown to attenuate 
oxidative DNA damage induced by advanced glycation end-products (AGEs) in rats [65]. The 
flavonol quercetin (QUE) has been reported to protect HepG2 cells against tert-butyl 
hydroperoxide mediated oxidative stress [66]. Finally, rosmarinic acid (ROSAC) has been 
shown to decrease OTA induced cytotoxicity in HepG2 liver cells [67] The effect of vitamin E 
and polyphenols on OTA induced cytotoxicity are described in chapter three.  
However, we did not only try to protect HepG2 cells from OTA induced cytotoxicity by radical 
scavenging antioxidants, but also by treatment of the cells with N-acetylcysteine (NAC), a 
precursor of the tripeptide glutathione (GSH), which is the most important water soluble 
cytosolic antioxidant and a substrate of many detoxifying enzymes in liver and kidney [68, 
69]. As controls, we exposed the cells to buthionine sulfoximine (BSO) which is well-known 
to deplete cellular GSH by inhibiting the rate limiting enzyme of GSH synthesis, γ-
glutamylcysteinyl synthetase (γ-GCS) [70]. In addition, we determined total GSH levels in 
response to BSO, NAC, and OTA treatment (Chapter four).  
Since little is known regarding the transcriptional alterations underlying OTA derived toxicity, 
another focus of our studies was to determine the impact of OTA on gene expression and 
transcription factor activity. In recent studies it has been reported that OTA may affect Nrf2 
signal transduction pathways [71, 72]. Nrf2 is a basic leucine zipper transcriptional activator 
essential for the coordinated transcriptional induction of antioxidant and xenobiotic 
metabolizing enzymes in the kidney including γ-glutamylcysteinyl synthetase (γ-GCS) and 
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glutathione-S-transferase (GST). Therefore we investigated the effect of OTA on the mRNA 
levels of Nrf2, γ-GCS, and GST (Chapter five). So far, to the best of our knowledge, large-
scale gene chip studies regarding the gene regulatory activity of OTA have only been 
performed in rat kidney cells [73]. However, much less information is available if and to what 
extent OTA affects gene expression in the hepatic tissue. This brought us to perform a large-
scale gene expression profile of OTA exposed HepG2 liver cells using Affymetrix GeneChip 
technology aiming to identify molecular targets affected by OTA (Chapter six).  
Finally, the last chapter (Chapter seven) is a general discussion, in which our experimental 
data are critically discussed in the context of the international literature.  
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   CHAPTER TWO 
Abstract. Vitamin E has been described in the literature as a
regulator of gene expression. The gene-regulatory activity of
vitamin E with regard to genes encoding cytochrome P450
(CYP) enzymes, which play a pivotal role both in the
metabolism of xenobiotics and vitamin E, has not been
conclusively characterised. The objective of the current study
was, therefore, to elucidate the short- and long-term effects of
natural and synthetic vitamin E on CYP gene expression using
Affymetrix GeneChip® technology. To this end, HepG2 cells
were incubated with 0, 10, 30, 80 and 300 ÌM RRR-·-
tocopheryl acetate (natural vitamin E) or all rac-·-tocopheryl
acetate (synthetic vitamin E) for 7 days and the mRNA of CYP
genes was quantified. The expression of only one (CYP20A1)
of 14 CYP genes with detectable mRNA levels was dose-
dependently up-regulated. No differences in gene-regulatory
activity were observed between RRR- and all rac-·-tocopheryl
acetate. To study the role of vitamin E in CYP gene expression
in vivo, Fisher 344 rats were randomly assigned to either a
vitamin E-enriched (60 mg/kg RRR-·-tocopheryl acetate) or -
deficient (1.7 mg/kg RRR-·-tocopheryl acetate) diet for 290
days. Neither in the vitamin E-enriched, nor in the vitamin E-
deficient rats, were significant changes in the liver CYP, mRNA
levels observed. In conclusion, our data indicated that vitamin
E does not appear to modulate cytochrome P450 mRNA
expression in HepG2 cells or in rats. 
·-Tocopherol, the predominant form of vitamin E in vivo,
is the most important lipid-soluble, chain-breaking anti-
oxidant in human plasma (1). In the past, studies have
focussed on the ability of vitamin E to prevent diseases that
are believed to have an oxidative stress component, such as
atherosclerosis, Alzheimer’s disease and cancer (2-4).
However, more recent findings have indicated that vitamin
E also has other important functions that are independent
of its anti-oxidant activity, such as the regulation of gene
expression (5-8).
Vitamin E is not one particular substance, but a generic
term for a group of lipid-soluble, chain-breaking anti-
oxidants. The eight recognized natural vitamin E
compounds consist of a chromanol head substituted with a
16-carbon side chain. They can be subdivided into
tocopherols, with a saturated side chain and tocotrienols,
with an unsaturated side chain with three isolated double
bonds. The lower case greek letters ·, ‚, Á, ‰ are assigned
as prefixes according to the number and position of methyl
groups attached to the chromanol head. Because the side
chain of the tocopherols features three chiral centres at
positions 2, 4’, and 8', that can be in either R or S
configuration, eight stereoisomers for each tocopherol are
possible. In nature, tocopherols exist exclusively as RRR-
stereoisomers, whereas synthetic vitamin E is an equimolar
mixture of all eight stereoisomers, a so-called all racemic (all
rac) mixture (9).
Upon ingestion, vitamin E generally follows the
absorption and transport pathways of dietary lipids in the
body. The metabolic degradation of vitamin E seems to
occur in the liver, involving cytochrome P450 (CYP)
enzymes (10, 11). 
CYP enzymes constitute a large family of membrane-
bound oxidative proteins. In liver cells, CYPs are located
either in the inner membrane of the mitochondria or in the
endoplasmic reticulum, where they metabolize a wide
variety of endogenous compounds and xenobiotics. They
are, however, also present in other tissues of the body
including the mucosa of the gastrointestinal tract and kidney
cells. In mammals, CYP enzymes are the most important
enzymes of phase I metabolism. Additionally, they play an
183
Correspondence to: Dr. Luca Barella, Institute of Human Nutrition
and Food Science, Christian-Albrechts-University, Hermann-
Rodewald-Strasse 6, D-24118 Kiel, Germany. Tel: +41 61 688
5292, Fax: +41 61 688 1640, e-mail: luca.barella@dsm.com
Key Words: Vitamin E, cytochrome P450, gene expression, rat,
liver, HepG2.
CANCER GENOMICS & PROTEOMICS 3: 183-190 (2006)
Effect of Vitamin E on Cytochrome P450 mRNA Levels 
in Cultured Hepatocytes (HepG2) and in Rat Liver
CHRISTOPH HUNDHAUSEN1, JAN FRANK1, GERALD RIMBACH1, 
ELISABETH STOECKLIN2, PATRICK Y. MULLER2 and LUCA BARELLA2
1Institute of Human Nutrition and Food Science, Christian-Albrechts-University, 
Hermann-Rodewald-Strasse 6, D-24118 Kiel, Germany;
2DSM Nutritional Products, Research and Development, P.O. Box 3255, CH-4002 Basel, Switzerland
1109-6535/2006 $2.00+.40
important role in the biosynthesis of steroids, fatty acids and
bile acids. In humans, CYP3A4 and its closely related form
CYP3A5 are the most abundant forms in the liver (from 30
to 60% of total CYP, depending on genetic background,
food etc.). CYP3A4 metabolises more than 50% of the
drugs currently used for therapy (12). 
The initial step in the metabolism of tocopherols and
tocotrienols is the hydroxylation of the terminal methyl
group of the side-chain, followed by a step-wise
shortening by ‚-oxidation. The resulting water-soluble
carboxye-thylhydroxychromans (CEHCs) are excreted in
the urine. Both CYP4F2 and CYP3A4 were suggested to
facilitate this initial ˆ-hydroxylation and their inhibition
resulted in a reduced production of CEHCs in various in
vitro systems (13, 14).
High-throughput techniques for the analysis of changes in
mRNA levels are powerful tools to study the gene-regulatory
activity of vitamin E. These state-of-the-art techniques have
been successfully used to identify genes that are differentially
expressed in response to dietary vitamin E in various tissues
including liver (5), testes (6) , adrenal glands (15), cortex
(16) and hippocampus (7). Although some studies indicate
an induction of CYP mRNA by certain vitamin E isoforms
(11, 17), the role of the vitamin on the expression of CYPs
has not been studied in sufficient detail. 
The aim of this trial was to perform a large-scale gene-
chip experiment to determine the role of vitamin E on the
gene expression of CYP enzymes both in vitro and in vivo. 
Materials and Methods
Cell culture experiments. HepG2 cells (ATCC HB-8065) were
cultured in 6 cm dishes in DMEM medium (GIBCO-Invitrogen,
Basel, Switzerland) with 10% NU serumì (Becton Dickinson,
Basel, Switzerland) containing 1% penicillin/streptomycin and no
detectable amounts of vitamin E (detection limit 20 nM). RRR- and
all rac-·-tocopheryl acetate (purity: 99.0-99.5 and 98.0-99.5
weight%, respectively, DSM Nutritional Products Ltd, Kaiseraugst,
Switzerland) were dissolved in 100% ethanol to prepare stock
solutions. Treatment media were prepared by the addition of
RRR- or all rac-·-tocopheryl acetate (RRR-·-Tac or all rac-·-Tac,
respectively) to the basic medium at the following final
concentrations: 0, 10, 30, 80 and 300 ÌM. The maximal ethanol
concentration in the medium was 1ò. Treatment media were
aliquoted and stored at –20ÆC. The vitamin E treatment was
performed for seven days during the logarithmic growth phase of
the cells. All treatment media were exchanged for fresh media
every 24 h. All treatments were performed in quadruplicate dishes.
Animals and diets. Sixty recently-weaned male Fisher 344 rats
(Charles River, Les Oncins, France) with an initial average weight
of 50-60 g were randomly assigned to either a VE-containing diet
(VE+) or to a control diet deficient in vitamin E (VE) for 290
days. The VE+ diet contained 60 mg/kg RRR-·-tocopheryl acetate
(DSM Nutritional Products Ltd), which corresponds to 80 IU per
kg diet. The VE-diet contained 60 mg/kg of the vehicle (16% fish
gelatine, 8% micro gel E, 1% Sipernat 50) resulting in a final
dietary concentration of 1.7 mg/kg RRR-·-tocopheryl acetate. The
VE- and VE+ rats consumed the diets ad libitum and had free
access to water. The rats were maintained under standard
conditions at 22±1ÆC with 12:12 h dark:light cycles. The
Laboratory Animal Care Committees of F. Hoffmann-La Roche
Ltd, Basel and the Veterinary Office of Basel-Stadt, Switzerland
approved all animal protocols.
Beginning from day 17 of feeding, five animals per group were
euthanised every 3 months under isoflurane anaesthesia by
withdrawing blood from the vena cava. Livers were removed,
rinsed in ice-cold phosphate-buffered saline (pH 7.4) and snap-
frozen in liquid nitrogen. Samples were stored at –80ÆC prior to
RNA extraction.
Vitamin E concentrations in HepG2 cells and in rat liver and plasma.
Adherent HepG2 cells were trypsinised, collected and washed
three times with PBS containing 1% bovine serum albumin. The
HepG2 cells or liver tissue, respectively, was saponified in a
methanolic potassium hydroxide solution. The solution was diluted
in 35% ethanol and extracted with hexane/toluol. ·-Tocopherol
was quantified by isocratic HPLC analysis using a Lichrosorbì Si
60.5 mm, 20x4 mm pre-column coupled to a Lichrosorbì Si 60.5 mm,
125x4 mm column (Stagroma, Reinach, Switzerland) and 3% 1.4-
dioxane in n-hexane as the mobile phase (flow rate ~1.6 ml/min,
pressure 35-55 bar). Fluorescence was measured at 330 nm after
excitation at 295 nm. 
The plasma samples were analysed for ·-tocopherol using a
routine HPLC method. Briefly, the plasma proteins were
precipitated using ethanol and tocopherol was extracted by
liquid/liquid extraction with hexane. After centrifugation, an
aliquot of the organic phase was chromatographed isocratically on
a normal phase HPLC system. ·-Tocopherol was quantified by
fluorimetry (excitation at 298 nm, emission at 326 nm).
Total RNA extraction, cRNA preparation and Affymetrix GeneChip®
hybridization. The cells were washed three times with PBS and
lysed with RTL buffer (Qiagen, Basel, Switzerland). Total RNA
isolation was performed using RNeasy mini spin columns (Qiagen)
and DNase digested on the columns (RNase-Free DNase Set,
Qiagen) according to the manufacturer’s description. cRNA
preparation and Affymetrix GeneChip® (U133A) hybridisation
were performed as described (5).
GeneChip® microarray expression and data analysis. Data processing was
carried out using the RACE-A analysis tool (Roche Bioinformatics,
Basel, Switzerland) as previously described (5). Briefly, the arrays were
normalised against the mean of the total sum of Average Difference
(AvgDiff) values across all arrays used. Mean average difference values
(MeanAvgDiff) were calculated as the means of one experiment
performed in quadruplicate. Possible outliers were identified using the
procedure of Nalimov with a 95% confidence interval. Subsequently,
mean change factors (Chgf) for each individual gene were calculated
among the different treatment groups and control using pairwise
comparisons and statistical significance was assessed by the Student’s
t-test with prior testing for the normal distribution of the data. The
analysis of the experimental data obtained upon stimulation of the
HepG2 cells with RRR-·-Tac or all rac-·-Tac was performed
independently from each other. Confirmation of the gene expression
data by RT-PCR was omitted because, in previously published
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experiments performed on the same experimental animals, the
GeneChip® data were always consistent with data confirmed by
independent methods (5-7). A differential expression profile analysis
between the two treatment groups was performed at four different
time-points (T1=day 17, T2=day 91, T3=day 191 and T4=day 269 of
feeding) over the 9-month study period in five individual liver samples.
Results
·-Tocopherol concentrations in HepG2 cells. The incubation
of HepG2 cells with media containing 0, 10, 30, 80 or 300 ÌM
RRR- or all rac-·-Tac for 7 days dose-dependently increased
the intracellular content of free vitamin E. A plateau was
reached at supplementation with 80 ÌM vitamin E and a
further increase in vitamin E did not cause higher
intracellular vitamin E concentrations. There was no
significant difference between the intracellular concentrations
of RRR- and all rac-·-Tac (data not shown).
CYP mRNA expression in vitro. In the HepG2 cells, 14 out of
the 44 CYP enzymes represented on the RNA microarray
were expressed. The highest expression levels of these 14
CYPs were observed for CYP27A1 and CYP51A1 (Figure
1). Four members of the CYP3A subfamily, namely CYP3A4
(Figure 1), CYP3A5, CYP3A7 and CYP3A43, as well as
CYP4F3 and CYP4F12, showed low to moderate expression
levels. CYP4F2 was only marginally expressed.
In response to vitamin E supplementation, only the
mRNA levels of CYP20A1 dose-dependently increased
(Figure 1). All other 13 CYPs with detectable mRNA levels
showed no dose-dependency. Moreover, there was no
substantial difference in CYP mRNA expression between
treatment with RRR-·-Tac and all rac-·-Tac. A detailed list
of the CYP mRNA levels for each vitamin E concentration
is given in Table I.
Body weight, plasma and liver vitamin E concentrations in rats.
No differences in weight gain and final body weight were
observed between the rats fed VE+ and VE– diets. Rats fed
the VE+ diet had significantly higher plasma levels (27.40±3.17
Ìmol/l, day 269) compared to the controls receiving the VE–
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Figure 1. Cytochrome P450 mRNA levels in HepG2 cells – given in arbitrary units (a.u.) – after treatment with RRR-·-tocopheryl acetate ("RRR") or
all rac-·-tocopheryl acetate ("all rac") at the concentrations given for 7 days. The data represent means±SD.
diet (0.20±0.09 Ìmol/l, day 269). Differences in dietary 
·-tocopherol were also reflected by significant differences in its
hepatic concentrations after 269 days (VE+: 83.91±15.86
nmol/g tissue, VE–: 0.35±0.20 nmol/g tissue) (5).
CYP mRNA expression in vivo. In rat liver, 34 out of the 44
CYP enzymes represented on the RNA microarray were
expressed. The highest mRNA expression levels were observed
for CYP2C7 and CYP2D3. CYP3A4 and CYP4F2 also
showed high expression levels (Figure 2). CYP1A1, CYP2A3,
CYP2D18, CYP3A2, CYP3A9, CYP4A8, CYP11B3, CYP17
and CYP51 were only marginally expressed (data not shown).
A detailed list of all the CYPs with moderate or high mRNA
expression levels is given in Table II.
No significant differences in CYP mRNA concentrations
were found at any time between rats deprived of or
supplemented with vitamin E. Furthermore, no significant
changes in mRNA levels were observed over time.
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Table I. Cytochrome P450 mRNA levels in arbitrary units (a.u.) in HepG2 cells after treatment with RRR-·-tocopheryl acetate (“RRR”) and all rac-·-
tocopheryl acetate (“all rac”) at the concentrations indicated for 7 days. Data represent means±SD.
CYP450 enzyme, mRNA expression 
HepG2 (a.u.±SD)
Function VE form 0 10 30 80 300 ÌM VE
CYP1A2 metabolism of “all rac” 45 (15) 67 (10) 56 (5) 74 (5) 63 (1)
xenobiotics, drugs “RRR” 45 (15) 62 (21) 64 (12) 67 (1) 48 (9)
CYP2A6 metabolism of “all rac” 72 (18) 61 (16) 54 (13) 44 (2) 43 (6)
xenobiotics, drugs “RRR” 72 (18) 59 (11) 75 (3) 45 (13) 53 (2)
CYP2C9 metabolism of “all rac” 66 (10) 36 (8) 34 (6) 42 (3) 35 (1)
xenobiotics, drugs “RRR” 66 (10) 45 (24) 65 (6) 36 (4) 37 (1)
CYP3A4 metabolism of “all rac” 48 (3) 35 (7) 31 (6) 28 (4) 29 (4)
xenobiotics, drugs “RRR” 48 (3) 35 (7) 38 (17) 20 (4) 34 (5)
CYP3A5 metabolism of “all rac” 36 (9) 23 (4) 23 (2) 38 (9) 24 (1)
xenobiotics, drugs “RRR” 36 (9) 28 (6) 29 (6) 37 (3) 25 (4)
CYP3A7 metabolism of “all rac” 38 (13) 25 (12) 27 (8) 26 (5) 23 (1)
xenobiotics, drugs “RRR” 38 (13) 29 (7) 34 (10) 25 (1) 22 (5)
CYP3A43 metabolism of “all rac” 45 (12) 45 (2) 40 (9) 46 (5) 34 (3)
xenobiotics, drugs “RRR” 45 (12) 31 (11) 39 (2) 38 (6) 41 (2)
CYP4F3 arachidonic acid “all rac” 37 (7) 18 (12) 23 (3) 26 (3) 20 (2)
or fatty acid metabolism “RRR” 37 (7) 26 (9) 24 (4) 24 (8) 20 (5)
CYP4F12 arachidonic acid or “all rac” 77 (21) 39 (10) 36 (2) 61 (6) 59 (8)
fatty acid metabolism “RRR” 77 (21) 55 (12) 61 (7) 47 (7) 51 (12)
CYP11B1 steroid biosynthesis “all rac” 35 (13) 13 (1) 21 (3) 21 (3) 15 (2)
“RRR” 35 (13) 25 (4) 29 (5) 18 (6) 17 (4)
CYP20A1 unknown “all rac” 64 (10) 82 (2) 105 (3) 130 (2) 132 (6)
“RRR” 64 (10) 72 (24) 91 (25) 115 (1) 119 (5)
CYP24A1 vitamin D degradation “all rac” 40 (8) 50 (1) 72 (10) 44 (8) 40 (7)
“RRR” 40 (8) 43 (4) 52 (13) 56 (10) 45 (6)
CYP27A1 bile acid biosynthesis “all rac” 435 (51) 430 (8) 420 (41) 463 (4) 418 (33)
“RRR” 435 (51) 386 (63) 488 (1) 410 (49) 359 (33)
CYP51A1 cholesterol biosynthesis “all rac” 323 (57) 219 (32) 220 (9) 239 (38) 246 (20)
“RRR” 323 (57) 201 (9) 245 (31) 294 (1) 200 (24)
Discussion
The objective of this study was to investigate the short-
and long-term effects of vitamin E on CYP mRNA
expression. To this end, HepG2 cells were supplemented
with RRR- or all rac-·-tocopheryl acetate at
concentrations of 0, 10, 30, 80 and 300 ÌM. Only
CYP20A1 mRNA was dose-dependently up-regulated by
vitamin E in vitro. The function of CYP20A1 in humans is
currently unknown. Its amino acid sequence has a 23%
similarity to that of rat CYP17A1, which is known to be
involved in sexual development during foetal life and at
puberty (18, 19). CYP20A1 may play a role in the
metabolism of human sex hormones. This is consistent
with the discovery of vitamin E as an essential factor for
successful reproduction in rats (20).
The remaining 13 CYP enzymes expressed in HepG2
cells showed no dose-dependent regulation by vitamin E.
Previously, incubation of human HepG2 cells with a single
dose of 50 ÌM Á-tocotrienol, a different form of vitamin E,
for 48 hours, resulted in a significant up-regulation of
CYP3A4 and CYP3A5 mRNA (21). However, Á-tocotrienol
is usually not detectable in human plasma. Supplementation
with 250 mg tocotrienols/d for 8 weeks did not raise the
plasma tocotrienol concentrations above 1 mM (22). Thus,
the Á-tocotrienol concentrations used by Landes and co-
workers are not physiologically achievable and the
significance of their findings await confirmation or
refutation in properly designed in vivo experiments.
Moreover, in our study, the HepG2 cells were
supplemented with vitamin E for 7 days, because we
thought it important to keep the vitamin E concentrations
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Figure 2. Cytochrome P450 mRNA levels in rat hepatocytes – given in arbitrary units (a.u.) – after treatment with a vitamin E-enriched diet (60 mg/kg
RRR-·-tocopheryl acetate, VE+) or a vitamin E-deficient diet (1.7 mg/kg RRR-·-tocopheryl acetate, VE–) for 17 d (T1), 91 d (T2), 191 d (T3) or 269
d (T4). The data represent means±SD.
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Table II. Cytochrome P450 mRNA levels in arbitrary units (a.u.) in rat hepatocytes after treatment with a vitamin E-enriched (60 mg/kg RRR-·-
tocopheryl acetate, VE+) or a vitamin E-deficient diet (1.7mg/kg RRR-·- tocopheryl acetate, VE–) for 17 d (T1), 91 d (T2), 191 d (T3) or 269 d (T4)).
The data represent means±SD.
CYP450 mRNA expression
enzyme, rat (a.u.±SD)
Function VE form T1 T2 T3 T4
CYP1A2 may play a role in VE– 2910 (14) 2202 (10) 2098 (50) 4583 (9)
xenobiotic metabolism VE+ 2420 (16) 1826 (39) 1524 (14) 2389 (40)
CYP2A1 steroid hormones VE– 8842 (552) 7758 (742) 7268 (225) 6883 (1543)
7-alpha-hydroxylase VE+ 7169 (735) 6717 (48) 7858 (431) 7324 (596)
CYP2A2 testosterone VE– 6583 (59) 5464 (19) 5688 (39) 7353 (46)
15-alpha-hydroxylase VE+ 6307 (46) 4816 (45) 5367 (12) 7470 (6)
CYP2B2 unknown VE– 3943 (37) 887 (32) 1529 (49) 2007 (57)
VE+ 3598 (40) 1095 (35) 1896 (20) 2694 (40)
CYP2B3 oxidises a variety of VE– 6958 (6) 6868 (55) 5258 (20) 6260 (41)
compounds, including VE+ 6973 (46) 7713 (38) 8621 (4) 6866 (38)
steroids, fatty acids, xenobiotics
CYP2C6 may play a role in VE– 9635 (208) 5583 (489) 5374 (197) 6885 (298)
drug metabolism VE+ 8584 (384) 4252 (258) 7225 (441) 7068 (431)
CYP2C7 a retinoic acid and VE– 12482 (41) 13689 (94) 11292 (27) 8682 (327)
testosterone hydroxylase VE+ 13257 (53) 12374 (11) 9144 (41) 8596 (103)
CYP2C11 unknown VE– 6673 (363) 10021 (872) 7935 (461) 4656 (1376)
VE+ 7126 (356) 10949 (79) 8516 (299) 5578 (723)
CYP2C13 metabolizes arachidonic acid VE– 7322 (9) 5767 (6) 6166 (3) 4649 (60)
VE+ 8921 (7) 6074 (13) 5509 (16) 6034 (63)
CYP2C22 unknown VE– 6596 (48) 3190 (60) 4494 (57) 2914 (63)
VE+ 9940 (97) 3823 (35) 4627 (29) 5757 (9)
CYP2C23 arachidonic acid epoxygenase VE– 9266 (41) 10034 (18) 11794 (65) 12426 (82)
VE+ 10562 (34) 10174 (53) 12254 (19) 11044 (50)
CYP2D3 debrisoquine 4-hydroxylase VE– 12763 (277) 10947 (166) 11975 (167) 8467 (215)
VE+ 11433 (80) 11349 (64) 11863 (29) 8617 (93)
CYP2D4 debrisoquine 4-hydroxylase VE– 1323 (163) 1364 (81) 1332 (50) 754 (380)
VE+ 1139 (336) 1305 (243) 1153 (46) 705 (89)
CYP2D5 debrisoquine 4-hydroxylase VE– 6495 (80) 6068 (57) 6690 (36) 7071 (60)
VE+ 7849 (57) 5884 (5) 6652 (15) 8954 (32)
CYP2F4 unknown VE– 588 (16) 720 (27) 732 (15) 1117 (12)
VE+ 534 (16) 636 (7) 836 (18) 996 (25)
CYP2J3 unknown VE– 1505 (10) 1963 (19) 1316 (6) 1051 (100)
VE+ 1900 (21) 1602 (4) 1201 (6) 1494 (52)
CYP3A1 unknown VE– 8549 (433) 6776 (220) 10376 (111) 9472 (1082)
VE+ 9025 (276) 8143 (139) 10392 (227) 10079 (187)
CYP3A18 catalyses 16 beta- and 6-alpha VE– 3965 (34) 4531 (55) 3875 (43) 4086 (27)
hydroxylations of testosterone VE+ 3980 (29) 3808 (68) 5410 (36) 3839 (18)
continued
stable over time and to establish intracellular steady state
concentrations of vitamin E (23), whereas in most studies
reported in the literature, the incubation periods were only
24 or 48 h (14, 21). Thus, the previously reported changes
of CYP expression may be transient effects.
In our in vitro model, no significant differences were found
in CYP gene expression between the natural and synthetic
forms of vitamin E. This is in agreement with our previously
published data showing that RRR- and all rac-·-tocopherol
share identical transcriptional activity in HepG2 cells (23).
Feeding male rats over a period of 9 months with diets
deficient in (< 2 mg RRR-·-tocopheryl acetate/kg diet) or
supplemented with vitamin E (60 mg RRR-·-tocopheryl
acetate/kg diet; approximately twice the recommended 
·- tocopherol content of diets for growing rats (24)), resulted
in an almost complete depletion or a significant
accumulation of ·-tocopherol in the plasma and liver,
respectively (5). Despite these pronounced differences in the
plasma and liver ·-tocopherol concentrations, no changes in
gene expression of CYP enzymes were observed (Table II).
In previous experiments, the employed rat model was
successfully used to identify vitamin E-sensitive genes (5, 6).
Kluth et al. (17) fed mice for 3 months with diets
containing 2, 20, or 200 mg RRR-·-tocopheryl acetate/kg.
The hepatic levels of Cyp3a11 (the murine homolog of
human CYP3A4 and rat CYP3A1 (25)) mRNA were about
2.5-fold higher in the 20- and 200-mg ·-tocopherol groups
compared to the 2-mg group. Furthermore, after feeding
200 mg ·-tocopherol for 9 months, Cyp3a11 mRNA was
1.7-fold higher than after 3 months. The differences
between our results and those of Kluth et al. (17) may be
related to species-specific differences in the regulation of
CYP gene expression. It has been reported that the
induction of CYP3As by rifampicin is much more
pronounced in humans than in rodents (26), and that rat
CYP3A1 is not affected by rifampicin at all (27).
In conclusion, it was shown that vitamin E does not affect
the CYP mRNA levels of the majority of CYPs in HepG2
cells or in rat liver in vivo. Moreover, no differences between
natural and synthetic vitamin E on CYP gene expression
were observed. Since the current study measured the effect
of vitamin E on CYP gene expression at the level of mRNA,
future experiments are warranted to study these effects at
the level of CYP protein expression and enzyme activity.
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Ochratoxin A impairs Nrf2-dependent gene expression
in porcine kidney tubulus cells
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Introduction
Ochratoxin A (OTA) is an ubiquitous mycotoxin
mostly produced by Aspergillus and Penicillium subspe-
cies and present in feedstuffs (Bayman et al., 2002).
Ochratoxin A exerts various toxic effects including
nephro-, hepato-, terato-, immuno- and neurotoxic-
ity (Kuiper-Goodman and Scott, 1989; Petzinger and
Ziegler, 2000). The kidney is the main target tissue of
OTA toxicity (Castegnaro et al., 1998; Luehe et al.,
2003) and the chronic dietary exposure to OTA may
be linked to the pathogenesis of nephropathy, a
chronic tubulointerstitial kidney disease. Further-
more, OTA is considered as a key factor of porcine
nephropathy, which is endemic in Denmark (Elling
and Moller, 1973; Krogh, 1987, 1992). Currently, the
underlying mechanisms of OTA toxicity have not yet
been fully elucidated. Several mechanisms have been
proposed to explain OTA toxicity including inhibition
of protein synthesis (Dirheimer and Creppy, 1991),
mitchondrial activity alteration (Meisner and Chan,
1974) and oxidative stress (Petrik et al., 2003).
Recently, it has been proposed that OTA may affect
Nrf2 signal transduction pathways (Marin-Kuan
et al., 2006; Cavin et al., 2007). However, so far,
systematic studies in cell culture models also relevant
to animal nutrition are missing.
Under basal conditions, the transcription
factor Nrf2 is bound to the cytosolic Kelch-like
ECH-associated protein 1 (Keap1), a cysteine-rich
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Summary
The mycotoxin, ochratoxin A (OTA), which is produced by Aspergillus
and Penicillium subspecies, is frequently present in feedstuffs. Ochratoxin
A exhibits a wide range of toxic activities including nephrotoxicity.
However, the underlying molecular mechanisms of OTA-induced cellu-
lar nephrotoxicity have yet not been fully elucidated. Nrf2 is a basic leu-
cine zipper transcriptional activator essential for the coordinated
transcriptional induction of antioxidant and xenobiotic metabolizing
enzymes in the kidney. Therefore, in the present study, the effects of
OTA on the nuclear translocation and transactivation of the transcrip-
tion factor Nrf2 as well as mRNA levels of Nrf2 target genes including
glutathione-S-transferase and c-glutamylcysteinyl synthetase have been
studied in cultured porcine kidney tubulus cells (LLC-PK1). Nrf2 was
induced by sulforaphane, a well-known activator of this transcription
factor. Ochratoxin A significantly decreased c-glutamylcysteinyl synthe-
tase and glutathione-S-transferase mRNA levels in LLC-PK1 cells.
Decreased mRNA levels of c-glutamylcysteinyl synthetase and glutathi-
one-S-transferase were accompanied by a lowered nuclear translocation
and transactivation of Nrf2. Furthermore, OTA also lowered Nrf2 mRNA
levels. Current data indicate that OTA nephrotoxicity may be, at least
partly, mediated by an Nrf2-dependent signal transduction pathway.
DOI: 10.1111/j.1439-0396.2008.00838.x
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actin-associated repressor protein that keeps Nrf2
complexed in the cytosol (Dinkova-Kostova et al.,
2002; Itoh et al., 2003; Kang et al., 2004). Several
groups demonstrated the rapid degradation of Nrf2 by
the ubiquitin-proteasome pathway and the stabiliza-
tion of Nrf2 by phase II inducers like sulforaphane
(SFN) (Alam et al., 2003; Itoh et al., 2003; McMahon
et al., 2003; Nguyen et al., 2003). In the presence of
electrophilic substances, the Nrf2-Keap1 complex is
disrupted, Nrf2 translocates into the nucleus, binds to
the antioxidant response element (ARE) (Dinkova-
Kostova et al., 2002; Wakabayashi et al., 2004) and
controls the expression of phase II enzymes including
c-glutamylcysteinyl synthetase (cGCS) and gluta-
thione-S-transferase (GST) (McMahon et al., 2001;
Chanas et al., 2002). The aim of this study was to
further characterize the effect of OTA on the nuclear
translocation and transactivation of the transcription
factor Nrf2 as well as mRNA levels of Nrf2 and its
target genes including GST and cGCS in cultured
kidney tubulus cells derived from pigs.
Materials and methods
Chemicals
Ochratoxin A and SFN were obtained from Sigma
(Deisenhofen, Germany). An OTA stock solution of
25 mmol/l was prepared in methanol and stored at
)20 C. Sulforaphane was dissolved in dimethylsulf-
oxide (5 mmol/l stock solution) and stored at )20 C
until use. Cell culture medium and supplements
were obtained from PAA (Coelbe, Germany). Wes-
tern blotting reagents and materials were purchased
from Bio-Rad (Muenchen, Germany). All other
chemicals and reagents were acquired from Sigma,
unless specified otherwise.
Cell culture and treatments
Porcine renal epithelial proximal tubulus cells (LLC-
PK1) purchased from the Institute for Applied Cell
Culture (IAZ, Munich, Germany) were cultured in
Dulbecco’s modified Eagle’s medium with high glu-
cose content (4.5 g/l). Medium was supplemented
with 10% foetal bovine serum (FBS), 100 IU/ml
penicillin and 100 lg/ml streptomycin. Cells were
maintained in 75 cm2 flasks kept at 37 C under
standard conditions. A maximum of 15 in-house
passages were used for the experiments. Cells were
seeded at an initial density of 0.15 · 106 cells/cm2,
grown for 48 h and exposed to SFN, OTA and OTA
plus SFN at varying concentrations for different
time-points (6, 12 and 24 h). After treatment, cyto-
toxicity was measured via neutral red assay or cells
were harvested for Nrf2-dependent gene expression
and measurement of Nrf2-transactivation via repor-
ter gene assay and western blot analysis.
Determination of cell viability
The cytotoxicity of SFN, OTA and SFN/OTA in
LLC-PK1 was evaluated by the neutral red assay
(Borenfreund and Puerner, 1985). Cells seeded in 24-
well plates were treated with SFN (0–50 lmol/l), OTA
(0–50 lmol/l) and 5 lmol/l SFN/ 0–50 lmol/l OTA.
The medium was replaced after 24 h by medium con-
taining neutral red (50 lg/ml, Carl Roth, Karlsruhe,
Germany) and incubated for 3 h. Neutral red medium
was aspirated and cells were washed with phosphate
buffered saline (PBS). The incorporated neutral
red dye was extracted using a bleaching solution
(50% ethanol, 1% acetic acid, 49% H2O) and the
absorbance read at 540 nm using a plate reader
(Labsystems, Helsinki, Finland). Cell viability was
expressed as percent viability compared to non-
treated control cells.
Western blot analysis
LLC-PK1 cells were incubated with SFN and SFN plus
OTA supplemented medium for 6, 12 and 24 h. Cells
were harvested in PBS and centrifuged at 800 g (4 C,
3 min). The remaining cell pellet was resuspended in
10 mmol/l N-2-hydroxyethylpiperazine-N¢-2-ethane-
sulfonic acid (HEPES), pH 7.9 (10 mmol/l KCl,
1.5 mmol/l MgCl2, 0.5 mmol/l dithiothreitol, 0.1%
Nonidet-P40 and protease inhibitors) and incubated
on ice for 15 min and centrifuged (10 min, 4 C,
4000 g). The cell pellets were resuspended in ice-cold
40 mmol/l HEPES, pH 7.9 (400 mmol/l KCl, 1 mmol/
l dithiothreitol, 5 mol/l NaCl, 10% glycerol and prote-
ase inhibitors), left on ice for 30 min and centrifuged
at 18 000 g at 4 C for 30 min. Supernatants (nuclear
extracts) were removed and stored at )80 C until
further analysis. Protein concentrations of the samples
were determined by bicinchoninic acid (BCA) protein
assay (Pierce, Rockford, IL, USA). Thirty microgram
protein was mixed with loading buffer [0.5 mol/l Tris
buffer, pH 6.8, 87% glycerol, 10% sodium dodecyl
sulfate (SDS), 0.5% bromophenol blue, H2O, 0.05%
b-mercaptoethanol] and denaturated at 95 C for
5 min. Subsequently, the samples were separated on
a 10% SDS–polyacrylamide gel (Roth, Karlsruhe, Ger-
many) in Tris/Glycine/SDS buffer and blotted onto an
immunoblot polyvinylidene difluoride membrane.
The membrane was blocked with 3% non-fat dried
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milk in Tris-buffered saline, pH 7.4, in 0.05%
Tween-20 for 2 h and probed with polyclonal rabbit
anti-human Nrf2 primary antibody (Santa Cruz, Hei-
delberg, Germany) in a 1:500 dilution at 4 C over-
night. Then, the membrane was incubated with a goat
anti-rabbit IgG secondary antibody (1:4000) conju-
gated with horseradish peroxidase for 45 min. Specific
bands were visualized by enhanced chemilumines-
cence (ECL) reagent on a ChemiDoc system (both
Bio-Rad). The predicted size for Nrf2 is 68 kDa, which
corresponds to the lower band in the western blots.
The upper band (100 kDa) refers to the Nrf2/actin
complex, which is formed upon activation and
nuclear translocation of Nrf2 (Kang et al., 2002).
Transient transfection and luciferase reporter gene
assay
To investigate the effects of OTA on Nrf2-transacti-
vation and transcription of Nrf2 target genes, a pGL3
plasmid containing the ARE-motif from the rat
NQO1-promoter linked to a luc sequence was used.
The plasmids pARE_pGL3 of rat NQO1 (kindly pro-
vided by C. Wruck, University of Kiel, Germany),
pGL3, phRLTK (Promega, Mannheim, Germany)
were amplified in Escherchia coli BL 21 (Invitrogen,
Karlsruhe, Germany) grown in Luria Bertoni medium
supplemented with 100 lg/ml ampicillin at 37 C
overnight. Bacteria were harvested by centrifugation
and plasmid DNA was extracted by QIAprep Spin
Miniprep Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s description. LLC-PK1 cells
were seeded into 24-well plates, cultured for 24 h
and transfected with phRLTK (endogenous control)
and either pARE_pGL3 or pGL3 (control) using
FuGene HD transfection reagent (Roche, Mannheim,
Germany) for another 24 h. Following transfection,
cells were incubated with SFN (5 lmol/l), OTA (2.5,
10, 25 lmol/l) and SFN plus OTA (using concentra-
tions mentioned above) for another 24 h. Cell lysis
and determination of luciferase and renilla activity
were performed by a commercially available Dual
luciferase kit (Promega) according to the manufac-
turer’s instructions. Firefly and renilla luciferase
activities were measured in a luminometer (Tecan
GmbH, Crailsheim, Germany). Relative luciferase
activity was calculated by the firefly luciferase to
renilla luciferase ratio. The empty pGL3 plasmid
served as control. Luciferase activity of pARE_pGL3
plasmid without SFN treatment served as basis
(100% control) for OTA-treated cells, and SFN-
induced luciferase activity was used as basis (100%
control) for SFN/OTA-coapplied cells.
RNA isolation and real time PCR
To determine mRNA levels of Nrf2 and Nrf2 target
genes cGCS (heavy chain) and GST, LLC-PK1 cells
were stimulated for 12 h with the highest non-toxic
concentration of OTA (25 lmol/l), SFN (5 lmol/l)
and SFN plus OTA. After 12 h treatment, the cells
were washed with PBS and lysed with TRIsure
(Bioline, Luckenwalde, Germany). RNA was isolated
according to the manufacturer’s instructions. Total
RNA was quantified photometrically at 260 nm and
stored at )80 C until analysis. Quality of RNA was
determined by agarose gel electrophoresis. Primers
for human cGCS (as porcine sequence is unknown)
and porcine GST (no isoform-specified information
available) were designed by standard software tools
(Primer3, NCBI BLAST) and synthesized by MWG
(Ebersberg, Germany). Primer sequence information
is given below (Table 1). Real time PCR was per-
formed as one-step procedure with QuantiTect Sybr-
Green Kit from Qiagen (Hilden, Germany) on the
Rotorgene RG-3000 machine. Serial dilution of con-
trol cell RNA was used to generate standard curves
for calculation of sample mRNA level. Gene expres-
sion was normalized to the housekeeping gene
18SRNA and the results were calculated as per cent
of medium-treated control cells. PCR product size
was controlled by gel electrophoresis.
Statistical analysis
Results are expressed as mean ± SD. Statistical anal-
ysis was carried out with spss Version 15.0 (SPSS
GmbH Software, Munich, Germany). Normally
distributed data were compared via t-test; otherwise,
the non-parametric Mann–Whitney U-test was used.
Table 1 Primer sequences and conditions for
real time PCR experiments
Gene
Forward
primer
Reverse
primer
Annealing
temperature
18SRNA 5¢-AGTCGGCATCGTTTATGGTC-3¢ 5¢-CCGCAGCTAGGAATAATGGA-3¢ 57 C
cGCS 5¢-GGCGATGAGGTGGAATACAT-3¢ 5¢-CCTGGTGTCCCTTCAATCAT-3¢ 58 C
GST 5¢-CCTCCTATGGATGCGAAAAA-3¢ 5¢-ATGATATTGCGTGCGAACAA-3¢ 58 C
GCS, c-glutamylcysteinyl synthetase; GST, glutathione-S-transferase.
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Results
Cytotoxic effects of OTA and SFN on cell viability
To assure that SFN does not affect cell viability in the
following experiments, kidney cells were incubated
with increasing concentrations of SFN (1–50 lmol/l)
for 24 h. As shown in Fig. 1a, SFN did not influence
cell viability up to 10 lmol/l. However, 25 lmol/l led
to a 50% reduction of viability in LLC-PK1 cells and
50 lmol/l decreased viability approximately more
than 80% compared with control. Based on the cyto-
toxicity data, a SFN concentration of 5 lmol/l was
chosen for all further experiments.
To determine the toxicity of OTA, cell viability was
analysed following treatment of cells with increasing
concentrations of OTA ranging from 0 to 100 lmol/l
in control and SFN-supplemented medium. Ochratox-
in A and a co-treatment of OTA and SFN did not affect
cell viability up to 25 lmol/l. However, 50 and
100 lmol/l OTA reduced cell viability by 30% and
40% alone and in combination with SFN as shown in
Fig. 1b. Based on these findings, the highest non-
cytotoxic concentration of 25 lmol/l OTA was chosen
for all further experiments.
Effects of OTA and SFN on Nrf2 nuclear translocation
To study the translocation of the Nrf2 protein into
the nucleus after stimulation of LLC-PK1 with SFN
in the presence and absence of OTA, western blot
analyses were performed with nuclear extracts of
porcine kidney cells. As shown in Fig. 2, Nrf2
nuclear translocation was significantly induced by
SFN and decreased because of OTA treatment com-
pared with LLC-PK1 cells treated with SFN only.
Effects of OTA and SFN on Nrf2 transactivation
To investigate the effects of OTA, SFN and SFN/OTA
on ARE-dependent transactivation by Nrf2, kidney
cells were transiently transfected with ARE plasmid
constructs and transactivation was measured by a
luciferase reporter gene assay. As shown in Fig. 3,
SFN induced a threefold transactivation of Nrf2
whereas OTA lowered luciferase activity both in the
absence and presence of SFN.
OTA and SFN induced changes in gene expression
To study the effects of SFN, OTA and SFN/OTA on
the mRNA levels of Nrf2 and its target genes includ-
ing GST and cGCS, LLC-PK1 cells were stimulated
for 12 h with non-cytotoxic concentrations of OTA
and SFN. The effects of OTA, SFN and OTA plus SFN
on the transcriptional levels of GST, cGCS and Nrf2
are summarized in Fig. 4. Treatment of cells with
SFN significantly increased the mRNA level of GST
up to 1.5-fold, whereas OTA- and SFN/OTA adminis-
tration significantly decreased GST transcription
(Fig. 4a). Similar results were obtained in the case of
cGCS mRNA (Fig. 4b). Interestingly, OTA lowered
also Nrf2 mRNA levels (Fig. 4c).
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Fig. 1 (a) Sulforaphane (SFN)-, (b) ochratoxin
A (OTA)- and SFN/OTA- induced cytotoxicity in
LLC-PK1 cells. Cells were treated with increas-
ing concentrations of SFN and OTA and SFN/
OTA for 24 h. Cytotoxicity was determined
with neutral red assay and viability is
expressed as percentage of control cells. Data
represent mean + SD of three independent
experiments performed in triplicate.
Fig. 2 Western blot analyses of Nrf2 protein in nuclear extracts of
LLC-PK1 cells. Nuclear extracts were prepared from LLC-PK1 cells trea-
ted with sulforaphane and SFN ochratoxin A for 6, 12 and 24 h. Nrf2
translocates into the nucleus and binds to the antioxidant response
element motif in response to SFN exposure in a time-dependent man-
ner. In the presence of OTA, Nrf2 translocation decreases significantly.
The immunoblot shown is one representative out of three indepen-
dent experiments.
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Discussion
The mycotoxin OTA is a nephrotoxin and carcinogen
in rodents, whereas its potential cancer promoting
activity in humans is still under scientific debate
(Pfohl-Leszkowicz et al., 2007; Stefanovic´ et al.,
2007). Although the nephrotoxic potential of OTA
has been recognized for many years, the mecha-
nisms underlying its nephrotoxicity have not yet
been fully elucidated. It has been suggested that the
transcription factor Nrf2 may be implicated in OTA
toxicity (Marin-Kuan et al., 2006; Cavin et al.,
2007). Therefore, the present study aimed to further
characterize the impact of OTA on Nrf2 activation in
kidney cells.
OTA cytotoxicity
As the kidney is the main target organ of OTA, LLC-
PK1 cells, a porcine kidney cell culture model was
used. Several studies revealed relatively high OTA
concentrations in kidney cells following OTA expo-
sure probably as a result of the reabsorption of OTA
at all nephron segments (Gekle et al., 2005) and an
active transport of OTA via the organic anion trans-
porter (Jung et al., 2001). Concerning the suscepti-
bility of cells towards OTA, there are great
differences between various cell types. However, all
cells have in common that the cytotoxic effects of
OTA are time- and dose-dependent (Schaaf et al.,
2002; Baldi et al., 2004; Guerra et al., 2005;
Hundhausen et al., 2005). In addition, incubation
conditions substantially influence OTA toxicity in
cellular systems because the binding of OTA to
serum proteins from FBS supplementation prevents
its cellular uptake. However, many studies reported
in the literature were performed under serum-free
conditions (Schaaf et al., 2002; Baldi et al., 2004;
Guerra et al., 2005) leading to a cellular toxicity of
OTA which is approximately 10-fold higher com-
pared with experiments using serum (Schwerdt
et al., 1999; Boesch-Saadatmandi et al., 2006). For
the present investigation, cells were grown in med-
ium supplemented with 10% of FBS to provide opti-
mal growth conditions. Under these experimental
conditions, OTA did not exhibit any cytotoxic effects
400
***
200
250
300
350
0
50
100
150
Fi
re
fly
/re
ni
lla
 ra
tio
 [%
]
***
***
Control SFN OTA SFN/OTA
Fig. 3 Effect of ochratoxin A (OTA) on the antioxidant response ele-
ment (ARE)-dependent transactivation by Nrf2 in LLC-PK1 cells. Cells
were transfected with a pGL3 plasmid containing the ARE-motif (from
rat NQO1 promoter). Twenty-four hours after transfection, cells were
incubated with control medium or medium containing sulforaphane
(SFN, 5 lmol/l) supplemented with OTA (2.5, 10 and 25 lmol/l) for
24 h. Relative luciferase activity was determined by calculating the
firefly luciferase to renilla luciferase ratio. The transfected empty lucif-
erase plasmid (pGL3) served as a control. Values are means ± SD of
three experiments measured in quadruplicate. ***Significantly different
compared with control (p < 0.001; Mann–Whitney U-test).
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Fig. 4 Effects of ochratoxin A (OTA), sulforaphane (SFN) and SFN/OTA on glutathione-S-transferase (a), c-glutamylcysteinyl synthetase (b) and Nrf2
(c) mRNA levels in LLC-PK1 cells. Cells were incubated for 12 h with either 5 lmol/l SFN or 25 lmol/l OTA or co-incubated with 5 lmol/l SFN and
25 lmol/l OTA. Data represent mean ± SD of three experiments performed in duplicate. *Significantly different compared with control (p < 0.05;
Mann–Whitney U-test).
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in LLC-PK1 cells up to 25 lmol/l after 24 h incuba-
tion. However, it needs to be taken into account that
this OTA concentration is manifold higher than
those concentrations detected in animal and human
plasma (Studer-Rohr et al., 2000).
Modulation of Nrf2 nuclear translocation, transactiva-
tion and Nrf2-dependent gene expression by OTA
Sulforaphane significantly induced Nrf2 nuclear
translocation at any time-point studied. Nuclear
translocation is following disruption of Nrf2/Keap1
complex caused by SFN (Dinkova-Kostova et al.,
2002; Wakabayashi et al., 2004), which enhances
the level of Nrf2 as well as its stability (Jeong et al.,
2005). The Nrf2 protein seems to be stabilized and
protected from degradation by ubiquitin-proteasome
pathway as Nrf2 levels in the cytoplasm were not
changed (data not shown), whereas Nrf2 levels in
the nucleus were increased in response to SFN treat-
ment. The effect of OTA on nuclear translocation of
Nrf2 protein was investigated only in the presence of
SFN because protein activation is only evident after
stimulation. Interestingly, OTA decreased Nrf2 activ-
ity also on the mRNA level. The lowered Nrf2 mRNA
levels in the kidney after OTA treatment are possibly
caused by inhibition of its translocation into the
nucleus, which could be explained by the fact that
Nrf2 regulates its own gene expression (Kwak et al.,
2002).
It has been recently shown that SFN induces a
number of Nrf2-regulated genes (Thimmulappa
et al., 2002). Thus in this study, mRNA levels of
Nrf2-regulated enzymes including GST and cGCS
were analysed in response to OTA treatment. Gluta-
thione-S-transferase, a multigen family of enzymes,
detoxify endobiotic and xenobiotic compounds by
covalent linkage of glutathione to a hydrophobic
substrate forming less reactive and more polar gluta-
thione-S-conjugates, which are then eliminated via
urine (Eaton and Bammler, 1999). Six GST classes
have been described yet: GST-A, -M, -P, -T, -Z, -O
(Hayes et al., 2005), which exhibit a tissue- and spe-
cies-specific expression pattern. In pigs, however,
information regarding different subclasses of GST is
very limited. c-glutamylcysteine synthetase (also
known as glutamate cysteine ligase) is a key enzyme
in the glutathione biosynthesis pathway catalyzing
the synthesis of cGCS from l-glutamate and cysteine.
This reaction represents the rate limiting step in the
synthesis of glutathione, which is the most impor-
tant cytosolic antioxidant in the kidney (Lu, 1999;
Blokhina et al., 2003). In previous studies, the cellu-
lar content of glutathione in LLC-PK1 cells was sig-
nificantly decreased following OTA treatment, either
indicating an inhibition of cGCS expression by OTA
or an increased conjugation of OTA with glutathione
(Schaaf et al., 2002). The down-regulation of cGCS
by OTA is likely to result in chronic elevation of oxi-
dative stress in the kidney as reported previously
(Costa et al., 2007). One important finding of this
study is that OTA significantly decreased GST and
cGCS mRNA levels most likely via an Nrf2 signal
transduction pathway. As GST and cGCS are cen-
trally involved in OTA detoxification, our data indi-
cate that OTA may inhibit its own detoxification
machinery (Fig. 5).
Future in vivo studies are necessary to test the
hypothesis whether the finding in cultured porcine
kidney cells regarding the effect of OTA on Nrf2,
GST and cGCS have also relevance in pigs.
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Abstract 
Ochratoxin A (OTA) is a nephro- and hepatotoxic mycotoxin that frequently contaminates food and 
feedstuffs. Although recent studies indicate that OTA modulates renal gene expression, little is 
known regarding its impact on differential gene expression in the liver. We therefore performed a 
microarray study of the HepG2 liver cell transcriptome in response to OTA exposure (0; 0.25; 2.5 
µmol/l for 24 h) using Affymetrix GeneChip technology. Selected microarray results were verified by 
real-time PCR and Western blotting as independent methods. Out of 14500 genes present on the 
microarray, 13 and 250 genes were down regulated by 0.25 and 2.5 µmol/l OTA, respectively. 
Decreased mRNA levels of calcineurin A beta (PPP3CB) which regulates inflammatory signalling 
pathways in immune cells, and of the uncoupling protein 2 (UCP2) that has been suggested to 
control the production of reactive oxygen species (ROS), were observed in response to 0.25 µmol/l 
OTA. A particularly strong down regulation due to 2.5 µmol/l OTA was evident for the mRNA levels of 
the insulin-like growth factor binding protein 1 (IGFBP1) and tubulin beta 1 (TUBB1) which have been 
demonstrated to function as a pro-survival factor in hepatocytes and as an important cytoskeletal 
component, respectively. In addition, many genes involved in energy and xenobiotics metabolism, 
including phosphoglycerate kinase 1 (PGK1), stearoyl-Coenzyme A desaturase 1 (SCD), and 
glutathione S-transferase omega 1 (GSTO1) were down regulated by OTA. Furthermore, OTA 
significantly inhibited the capacitative calcium entry in HepG2 cells, indicating an alteration of 
calcium homeostasis. Overall, the present data indicate that OTA dose-dependently affects multiple 
genes encoding for key proteins of liver cell metabolism.  
 
Introduction 
OTA is produced by several Aspergillus and Penicillium species and was firstly isolated from Aspergillus 
ochraceus [1]. Chemically, OTA consists of a dihydroisocoumarin moiety linked to phenylalanine (Figure 1). 
Over the last years, ochratoxin A (OTA) which is frequently present in cereals [2], has received increasing 
attention because it has also been detected in relatively large amounts in non cereal plant products including 
coffee, nuts, spices, olives, grapes, and beans [3, 4]. Moreover, OTA has also been found in meat [5, 6] and 
in human blood, urine and milk [7-10]. Numerous animal studies demonstrated predominantly nephrotoxic, 
but also hepatotoxic, teratogenic, immunosuppressive, and recently also genotoxic effects of OTA [11-14]. 
The International Agency for Research on Cancer (IARC) classified OTA as a putative human carcinogen 
[15].  
The toxicity mechanisms of OTA are incompletely understood. Although it has been shown that OTA 
damages the mitochondria [16], inhibits protein biosynthesis [17] and causes oxidative stress [18, 19], little is 
known about the mode of action of OTA on the molecular level. Particularly, the impact of OTA on hepatic 
gene expression has remained elusive.  
A recent microarray study in primary rat kidney cells and a continuous kidney cell line revealed an influence 
of OTA on the transcription of genes involved in DNA repair, antioxidative defence, and inflammation [20]. 
Additionally, the study demonstrated that OTA modulates the same set of genes in vitro and in vivo. 
Moreover, recent data suggest an impairment of the “nuclear factor (erythroid-derived 2)-like 2” (Nrf2) 
dependent gene expression [21, 22]. 
Only a few hepatic genes have been reported to be affected by OTA including genes involved in the 
detoxification of reactive oxygen species (e.g superoxide dismutase) and in tumour development (e.g. 
connexin) [23]. Since the molecular targets of OTA are largely unknown we performed a large-scale gene 
expression profile to study the impact of OTA on the liver transcriptome using gene chip technology.  
 
Materials and Methods 
Cell culture, RNA isolation and microarray production 
HepG2 cells were seeded at a density of 2.5 x 105 cells/ml in six well plates (3 ml/well) and cultivated under 
standard conditions (RPMI-1640 medium with 10% foetal calf serum, 37°C, 5% CO2). At confluence two 
wells were treated identically with 0, 0.25 and 2.5 µmol/l OTA (Sigma, Deisenhofen, Germany) for 24 h. After 
washing twice with phosphate-buffered saline (PBS), cells of the identically treated wells were pooled and 
total RNA was extracted by use of the RNAeasy mini kit (Qiagen, Hilden, Germany). Treatment was 
repeated once in an independent experiment, resulting in a total of six RNA samples, two for each 
experimental condition (0, 0.25, and 2.5 µmol/l OTA) (n=2). Agarose gel electrophoresis was performed to 
check the RNA quality. Purity and concentration of RNA were determined spectrophotometrically at 260 nm 
(Beckman Coulter, Fullerton, USA). The six RNA samples were further processed for microarray 
hybridization as described in the “Affymetrix GeneChip Expression Analysis Technical Manual” by a regional 
German Affymetrix Service Provider, “KFB - Center of Excellence for Fluorescent Bioanalytics” (Regensburg, 
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Germany), resulting in six microarrays of the “Human Genome U133A 2.0” type that contains more than 
22000 probe sets representing 14500 well-characterized human genes. 
 
Real-time polymerase chain reaction (PCR; SybrGreen®) experiments 
For real-time PCR verification cell culture experiments were performed as described in the previous section 
with the exception that cells from identically treated cells were not pooled but RNA was isolated from cells of 
each single well of the cell culture plate. The procedure was repeated twice in independent experiments 
resulting in a total of 18 RNA samples, six for each experimental condition (0, 0.25, and 2.5 µmol/l OTA) 
(n=6). Primers were designed for glutathione S-transferase omega 1 (GSTO1), phosphoglycerate kinase 1 
(PGK1), stearoyl-Coenzyme A desaturase 1 (SCD), tubulin beta 1 (TUBB1), insulin-like growth factor binding 
protein 1 (IGFBP1), and the uncoupling protein 2 (UCP2) with standard software tools (Spidey, Primer3, 
NCBI BLAST) and synthesized by MWG (Ebersberg, Germany). Primer sequence information is given in 
Table 1. 
Real time PCR was performed as one-step procedure with the QuantiTect SybrGreen Kit (Qiagen) on the 
Rotorgene RG-3000 thermo cycler (Corbett Life Science, Sidney, Australia). Gene expression was 
normalized to the housekeeping gene 18SRNA (Qiagen) and results were calculated in percent of control 
cells.  
 
Microarray data analysis 
The raw data files (Cel files) were processed and normalized by dCHIP algorithm [24]. The gene expression 
values (arbitrary units, a.u.) were calculated with the “Perfect Match (PM) / Mismatch (MM) difference 
model”. In the following “Compare samples” analysis the two control arrays were firstly compared with the 
two “low dose” and secondly with the “high dose” arrays. For each gene the ratio of the mean expression 
values of control and experiment were calculated, resulting in the so-called “fold change” (FC) value. From 
the list of genes obtained we discriminated between genes with detectable (“present”) and undetectable 
(“absent”) expression values. Genes were selected on the basis of the following criteria: 1. “present” signal 
on all arrays, 2. “present” signal on both control arrays and “absent” signal on both experiment arrays, 3. 
“absent” signal on both control arrays and “present” signal on both experiment arrays. Furthermore, we 
selected for genes that showed a fold change ≥ + 2.0, or ≤ - 2.0 with P < 0.05. In order to exclude noise 
signals, genes with a mean expression level lower than 27 a.u. representing 5% of the mean control 
expression level, were not considered. Finally, we selected genes on the basis of reproducibility by 
considering only those genes that revealed similar expression values within the two control or the two 
experiment arrays (coefficient of variation of expression value ≤ 25%).  
 
Western blotting 
HepG2 cells were incubated with 0, 0.25 and 2.5 µmol/l OTA for 48 h, harvested in ice cold PBS and 
centrifuged. The remaining cell pellets were resuspended in RIPA buffer (25 mmol/l Tris/HCl pH 7.6, 150 
mmol/l NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) with protease inhibitor (Protease Inhibitor 
Cocktail, Sigma), and incubated on ice for 30 min. After centrifugation, supernatants were removed and 
stored at -80°C until further analysis. Protein concentrations of the samples were determined by BCA protein 
assay (Pierce, Rockford, Illinois, USA). 40 µg of protein was mixed with loading buffer (0.5 mol/l Tris buffer, 
pH 6.8, 87% glycerol, 10% SDS, 0.5% bromophenol blue, 0.05% β- mercaptoethanol) and denaturated at 
95°C for 5 min. Subsequently, the samples were separated on a 10% SDS/polyacrylamide gel (Roth, 
Karlsruhe, Germany) in Tris/Glycine/SDS buffer and blotted onto immuno-blot PVDF membranes. The 
membranes were blocked with 3% non-fat dried milk in Tris-buffered saline/Tween-20 (TBS/T) for 2 h and 
probed with the primary antibodies for IGFBP1 and GSTO1 (Santa Cruz, Heidelberg, Germany) at 4°C 
overnight (1:200 dilution). In the following, the membranes were incubated with goat anti-mouse IgG 
secondary antibodies (1:4000 dilution) (Santa Cruz, Heidelberg, Germany) conjugated with horseradish 
peroxidase for 45 min. Specific bands were visualized by ECL reagent on a ChemiDoc system (Bio-Rad).  
 
Measurement of intracellular Ca2+ (“Calcium imaging”) 
The impact of OTA on the intracellular calcium concentration of HepG2 cells was determined by 
fluorescence imaging. The acetomethyl ester of the fluorescent dye fura-2 (fura-2/AM) is an uncharged 
molecule that can easily permeate into the cell, where unspecific esterases cleave the lipophilic groups. This 
results in the charged form of the dye (referred to as fura-2) which binds to the target ion Ca2+. Upon calcium 
binding the fluorescent excitation maximum of fura-2 undergoes a blue shift from 380 nm (Ca2+-free) to 340 
nm (Ca2+-saturated). Therefore, the ratio of the emissions at those wavelengths is directly correlated to the 
amount of intracellular calcium.  
Fluorescence measurements were carried out with an inverted phase-contrast microscope (Axiovert 100, 
Zeiss, Oberkochen, Germany). Cells were excited alternatively at 340 or 380 nm and the light was deflected 
by a dichroic mirror into either the objective (Fluar 40×/1.30 oil, Zeiss, Oberkochen, Germany) or a camera 
(Proxitronic, Bensheim, Germany). Emitted fluorescence intensity was recorded at 505 nm and data 
acquisition was accomplished by using specialized computer software (Metafluor, Universal Imaging, 
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Downingtown, USA). As a measure for the increase of cytosolic Ca2+ activity, the peak of the change in the 
340/380 nm ratio was calculated for each experiment. 
HepG2 cells were pre-treated with 2.5 µmol/l OTA for 24 h at 37°C or left untreated and subsequently loaded 
with 3 µmol/l fura-2/AM for 30 min at 37°C. After running a baseline in the presence of extracellular Ca2+, 
changes in cytosolic Ca2+ were monitored upon depletion of the intracellular Ca2+ stores. Experiments were 
carried out prior to and during exposure to Ca2+-free solution. In the absence of Ca2+ the intracellular Ca2+ 
stores were depleted by inhibition of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) by thapsigargin 
(1 µmol/l). Store-depletion subsequently activates plasma membrane calcium channels, allowing an influx of 
calcium into the cytosol when calcium was re-added to the bath.  
Experiments were performed with Ringer solution containing: 125 mmol/l NaCl, 5 mmol/l KCl, 1.2 mmol/l 
MgSO4, 2 mmol/l CaCl2, 2 mmol/l Na2HPO4, 32 mmol/l Hepes, 5 mmol/l glucose, pH 7.4. Nominally Ca2+-free 
solutions contained: 125 mmol/l NaCl, 5 mmol/l KCl, 1.2 mmol/l MgSO4, 2 mmol/l Na2HPO4, 32 mmol/l 
Hepes, 0.5 mmol/l EGTA, 5 mmol/l glucose, pH 7.4. For calibration purposes ionomycin (10 µmol/l, Sigma, 
Germany) was applied at the end of each experiment. 
 
Results 
Microarray 
Out of 14500 genes represented on the array, 13 and 250 genes were at least twofold down regulated in 
response to 24 h treatment with 0.25 and 2.5 µmol/l OTA, respectively. 
Those 13 genes that were down regulated by 0.25 µmol/l OTA encode for proteins which are important in 
transcription, cell growth, cytoskeletal organization, immune response and energy metabolism (Table 2). The 
strongest down regulation (-3.9) due to 0.25 µmol/l OTA was observed for the insulin-like growth factor 2 
(IGF2). Furthermore, the calcineurin A beta (PPP3CB) gene and the “uncoupling protein 2” (UCP2) gene 
were both twofold down regulated. 
The fold changes of the 250 genes down regulated by 2.5 µmol/l OTA ranged from -2.0 up to -12.0. A 
classification of the 250 genes by fold change revealed as largest group (70%) the twofold down regulated 
genes (Figure 2). 10 genes (4%) were more than fivefold down regulated (Table 3). The highest fold change 
(-12.4) showed a gene called “death-inducer obliterator 1” (DIDO1). Glutathione S-transferase omega 1 
(GSTO1), one isozyme of the GST family, revealed a twofold down regulation of its mRNA levels, and the 
insulin-like growth factor binding protein 1 (IGFBP1) exhibited a fold change of -4.0 in response to OTA 
treatment. 
In addition, 33 genes that encode for proteins which are involved in the metabolism of carbohydrates and 
lipids were more than twofold down regulated, for example phosphoglycerate kinase 1 (PGK1) and stearoyl-
CoA desaturase (SCD) (Tables 4, 5a+b). Moreover, 2.5 µmol/l OTA decreased the mRNA levels of 16 genes 
predominantly involved in the cell cycle and the cell proliferation (Table 6). Out of the 28 down regulated 
mitochondrial genes the majority of genes encode for enzymes, mainly oxidoreductases such as isocitrate 
dehydrogenase 3 (NAD+) beta (IDH3B, Figure 3). 19 down regulated genes encode for proteins of the 
cytoskeleton including tubulin beta 1 (TUBB1, Figure 4). Furthermore, OTA decreased mRNA levels of three 
genes involved in calcium homeostasis, namely “chemokine (C-C motif) ligand 14” (CCL14), “CD24 
molecule” (CD24) and “ATPase, Ca++ transporting, cardiac muscle, slow twitch 2” (ATP2A2) (Table 7). An 
overview of gene classification by function and localization is given in Figures 5 and 6, respectively. 
 
Verification of microarray data by real-time PCR and Western Blots 
Lowered mRNA levels due to OTA could be verified for selected genes in independent experiments by real-
time PCR (TUBB1, IGFBP1, PGK1, SCD, UCP2 and GSTO1). However, despite of the same tendency of 
gene regulation, the remarkably strong down regulation (FC > -100) of TUBB1 and IGFBP1 mRNA levels 
resulted from PCR experiments was not observed in the microarray study. Furthermore, Western blots for 
IGFBP1 and GSTO1 indicate also changes on the protein level (Figures 7+8) in response to OTA treatment. 
A particularly strong down regulation by OTA on both the transcriptional and protein level was observed for 
IGFBP1.  
 
Intracellular Ca2+ imaging 
Figure 9 A shows that the basal fura-2 ratio (first 3 minutes in calcium containing bath solution) and, thus, the 
intracellular Ca2+ level was not significantly different between control and OTA treated cells. Removal of 
calcium from the bath led to a decrease in the intracellular Ca2+ concentration to similarly low levels in control 
and OTA treated cells. Addition of 1 µmol/l thapsigargin to the calcium free bath solution resulted in a slight 
increase in the fura-2 ratio (peak 1) with no difference in the peak amplitude between control and OTA 
treated cells. Re-addition of extracellular Ca2+ in the continuous presence of thapsigargin led to a strong 
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increase in the fura-2 ratio (peak 2). The peak amplitude of this second peak was significantly smaller in OTA 
treated cells. 
 
Discussion 
Our microarray study demonstrated that OTA lowered mRNA levels of genes centrally involved in liver cell 
metabolism. The decrease of mRNA levels could have been either due to a decreased mRNA stability or a 
decreased gene transcription following the OTA treatment. Importantly, the applied OTA concentrations 
(0.25 µmol/l and 2.5 µmol/l) did not impair cell viability over 24 h treatment as shown previously [25]. Thus, 
the present data are indicative for the gene regulating activity of OTA in viable cells. 
 
Dose dependent effects of OTA 
A 24 h treatment of HepG2 cells with 0.25 or 2.5 µmol/l OTA resulted in a twofold or stronger down 
regulation of 13 or 250 genes, respectively. This demonstrates that OTA at concentrations that have already 
been detected in serum of pigs (0.62 µmol/l) [26] and humans (4.5 µmol/l) [27] affects the transcriptome of 
liver cells in culture.  
The immune-relevant calcineurin A beta gene (PPP3CB, previous symbol CALNB) was dose-dependently 
down regulated in response to 0.25 and 2.5 µmol/l OTA (FC = -2.0 and -7.6, respectively). PPP3CB is one of 
three isoforms (alpha, beta, gamma) of calcineurin A, the catalytic subunit of the Ca2+/calmodulin dependent 
phosphatase calcineurin, which is essential for T cell activation and survival in mice [28]. On the protein level 
inhibition of calcineurin has been reported to be nephrotoxic [29]. The OTA induced inhibition of PPP3CB 
transcription suggets that calcineurin is a molecular target of OTA contributing to its nephrotoxic, and 
possibly also hepatotoxic effects.  
 
Protein metabolism 
The 250 genes down regulated in response to 2.5 µmol/l OTA were classified into clusters according to the 
biological function and localization of the encoded proteins (Figures 5 + 6). Whereas Creppy and coworkers 
related OTA induced inhibition of protein biosynthesis mainly to the inhibition of a single group of enzymes 
(aminoacyl-tRNA synthetases) involved in the translational process [30], our data show that OTA affects a 
large number of genes involved in protein metabolism. Clustering resulted in 66 down regulated genes which 
are involved in protein biosynthesis, proteolysis or posttranslational protein modification and mainly encode 
for protein phosphatases, ligases, transferases, and hydrolases. Overall, our results are in accordance with 
previous studies demonstrating an inhibitory effect of OTA on protein biosynthesis [17, 31, 32]. 
 
Carbohydrate metabolism  
Remarkably, all 12 genes of the cluster “carbohydrate metabolism” were down regulated in response to a 24 
h treatment with 2.5 µmol/l OTA (Table 4). These genes predominantly encode for proteins which are 
important in glycolysis, tricarboxylic acid cycle, and gluconeogenesis. For example, two genes encoding for 
key glycolytic enzymes, namely phosphofructokinase (PFK) and phosphoglycerate kinase 1 (PGK1), which 
catalyze the conversion of D-fructose 6-phosphate to D-fructose 1,6-bisphosphate and 1,3-
diphosphoglycerate to 3-phosphoglycerate, respectively, were both twofold down regulated.  
Interestingly, PGK1 may also act as a cofactor for polymerase alpha and, thus, probably influences DNA 
synthesis and cell cycle progression [33]. Because of these two important functions of PGK1 we aimed to 
confirm the microarray data for this gene by an independent method. Real-time PCR data for PGK1 also 
indicate a substantial down regulation due to OTA (Figure 7). In addition, the genes encoding for isocitrate 
dehydrogenase 3 (NAD+) beta (IDH3B) and isocitrate dehydrogenase 3 (NAD+) gamma (IDH3G), revealed 
fold changes of -2.0 and -2.5, respectively. IDH3B and IDH3G belong to the NAD (+)-dependent isocitrate 
dehydrogenases which catalyze the allosterically regulated rate-limiting step of the tricarboxylic acid cycle. 
Also, our study demonstrated a substantial down regulation of the mRNA level of phosphoenolpyruvate 
carboxykinase 2, a well-known key enzyme of gluconeogenesis in the liver. This is in line with the down 
regulation of the C/EBP beta transcription factor (FC = -2.4) that has been reported to regulate 
gluconeogenesis and phosphoenolpyruvate carboxykinase gene transcription [34].  
Taken together, our data suggest that OTA massively inhibits the carbohydrate metabolism on the cytosolic 
and mitochondrial level in HepG2 cells, and, thus, strongly impairs the cellular energy supply. 
Lipid metabolism 
As shown in Tables 5a + b OTA treatment of HepG2 liver cells resulted in a substantial change of mRNA 
levels of several genes involved in lipid metabolism. In this study we report that a gene encoding for a key 
regulator in cellular fatty acid composition, the stearoyl-CoA desaturase (SCD), was down regulated in 
response to OTA. This finding which derived from the gene chip analysis could be verified by real-time PCR 
as an independent method (Figure 7). 
SCD converts saturated fatty acids (SFAs) into monounsaturated fatty acids (MUFAs). Alterations in SCD 
mRNA levels could change the phospholipid composition and, thus, the fluidity of cell membranes which, in 
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turn, possibly damages the function of membrane-attached proteins. Interestingly, for OTA it has been 
shown in different tissues of rats (brain, pancreas, and kidney) that the activity of many membrane-bound 
enzymes, for example alanine aminopeptidase and gamma-glutamyl transferase, is impaired [35, 36]. 
In addition, hepatic SCD down regulation has been demonstrated to correlate with an increase of pro-
inflammatory cytokines [37] and with anorexic effects in mice [38]. Similarly, also OTA has been reported to 
cause inflammation and anorexia in several animal species [39, 40]. 
In conclusion, we propose that the OTA induced SCD gene down regulation, as observed in this study, may 
be involved in several well-known effects of OTA such as inhibition of membrane-bound enzymes, 
inflammation and anorexia.  
 
Cell cycle and cell proliferation 
We observed that OTA decreased the mRNA levels of several genes involved in cell cycle and cell 
proliferation (Tables 2 + 6), among them the insulin-like growth factor 2 (IGF2), the insulin-like growth factor 
binding protein 1 (IGFBP1) and tubulin beta 1 (TUBB1). IGF2 and IGFBP1 are part of a complex system 
(often referred to as the IGF "axis") consisting of two cell-surface receptors (IGF1R and IGF2R), two ligands 
(IGF1 and IGF2), a family of six high-affinity IGF binding proteins (IGFBP 1-6), as well as associated IGFBP 
degrading enzymes. The IGF “axis” has been shown to play an important role in the promotion of cell 
proliferation and the inhibition of cell death. Disruption of the IGF2 gene leads to growth deficiency in mice 
[41]. Similar effects have been observed for OTA: the foetuses of pregnant Wistar rats fed with different 
doses of OTA revealed dose dependent skeletal anomalies like incomplete closure of the skull and fused 
ribs [42]. As we demonstrated an almost fourfold down regulation of IGF2 this may contribute to the well-
known OTA induced skeletal malformations in animals. 
IGFBPs mainly serve as carrier proteins for IGF1 and IGF2 which show high sequence similarity to insulin. 
IGFBPs modulate IGF action in complex ways that involve both inhibiting IGF action by preventing binding to 
the IGF1 receptor as well as promoting IGF action possibly through delivering it to the receptor and 
increasing its half-life. Recently, however, it has been documented that IGFBP1 exhibits an important 
intracellular function that is independent of the interactions with the IGFs: Leu et al. found in HepG2 cells that 
IGFBP1 is a pro-survival factor that binds to the “BCL2-antagonist/killer (BAK) and antagonizes the pro-
apoptotic actions of the nuclear transcription factor p53 in mitochondria [43]. In our study we show that OTA 
significantly inhibited IGFBP1, both on the transcriptional and protein level (Figure 8 A). Thus, OTA possibly 
induces mitochondrial damage partly by preventing the anti-apoptotic effects of IGFBP1.  
TUBB1 is one of six isoforms of beta tubulin. Polymers of beta and alpha tubulin dimers form the 
microtubules that are one of the components of the cytoskeleton and part of the mitotic spindle. Several 
studies demonstrated that disruption of the cytoskeleton or impairment of the mitotic process leads to cell 
death [44]. Our microarray and PCR data reveal that OTA lowers TUBB1 mRNA levels. This finding is in line 
with a previous study demonstrating defects in spindle formation caused by OTA [45].  
Mitochondrial function 
Although it is known for more than 30 years that OTA impairs mitochondrial function, the underlying 
molecular mechanisms, especially on the transcriptional level, are not fully understood. It has been shown 
that OTA dose-dependently inhibits the respiratory chain of isolated rat liver mitochondria [46]. Also, 
abnormally shaped mitochondria have been detected in kidneys of chicks fed with OTA [47]. These results 
are in line with our observation that key genes of mitochondrial function are affected by OTA (Figure 3). In 
particular, genes encoding for oxidoreductases such as IDH3B and IDH3G (we discussed these proteins in 
the section “carbohydrates”), were significantly down regulated by OTA. Furthermore, also mRNA levels of 
the uncoupling protein 2 (UCP2) gene, that has been shown to limit the generation of reactive oxygen 
species (ROS) in mice [48], were down regulated by OTA (verified by real-time PCR) indicating that an 
impairment of this gene might be a factor of the often reported OTA induced increase of oxidative stress [18, 
19]. 
 
Impact of OTA on calcium homeostasis 
Over the past two decades several studies demonstrated an effect of OTA on cellular calcium homeostasis 
in different cell types  [49-52]. Whereas some studies report an increase of cellular calcium induced by OTA 
[49, 53], others showed an inhibition of cellular calcium uptake [50, 51]. However, no data were available 
elucidating the impact of OTA on calcium homeostasis in HepG2 cells. In this study we demonstrated that 
OTA (2.5 µmol/l, 24 h) substantially decreased the calcium influx in HepG2 cells induced by depletion of 
intracellular calcium stores (Figure 9), which points to an inhibitory effect of OTA on store-operated Ca2+ 
channels (SOCs). This result is in line with previous in vitro studies showing a concentration-dependent 
inhibition of calcium uptake by OTA in liver and kidney microsomes [50, 51]. As blocking of Ca2+ entry has 
been shown to limit proliferation of cancer cells in vitro [54], the inhibition of calcium influx by OTA could well 
contribute to the OTA induced reduction of cell numbers that has been observed in many cell lines [55]. 
Furthermore, we identified four genes involved in calcium homeostasis and down regulated by OTA, namely 
CCL14, CD24, ATP2A2 and PPP3CB (Table 7). CCL14, for example, represents one of several CC cytokine 
genes and has been shown to raise intracellular Ca2+ in human monocytes and to enhance the proliferation 
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of human bone marrow cells [56]. Down regulation of this cytokine gene by OTA is consistent with our 
observed inhibition of calcium influx and the previously described immunosuppressive effects of OTA [57, 
58]. Cellular Ca2+ homeostasis may further be affected by down regulation of the ATP dependent ATP2A2 
gene, encoding for an intracellular calcium pump of the SERCA type. 
 
Conclusion 
Overall, our results indicate that OTA affects multiple genes encoding for key proteins of liver cell metabolism 
in cultured HepG2 hepatocytes. We have decided to perform our studies in HepG2 cells since they are of 
human origin, well characterized, widely used for toxicity studies [59], and sensitive towards OTA treatment 
[25, 60]. Furthermore, HepG2 cells are an excellent model to investigate mitochondrial toxicity because of 
their high content of organelles and mitochondrial DNA [61]. However, a limitation of the HepG2 model is 
that these cells do not express some phase II enzymes to the same extend like primary hepatocytes [62]. 
Finally studies in laboratory animals are warranted to test the effect of OTA on liver cell metabolism in vivo. 
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Table 1 Primer sequences and conditions for real time PCR experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Forward primer Reverse Primer Annealing Temperature
TUBB1 CAAAAGCATGACAGGCAGAA GGACAATTTCACGCATCCTT 57°C
IGFBP1 CTGCCAAACTGCAACAAGAA TATCTGGCAGTTGGGGTCTC 57°C
PGK1 CTGTGGGGGTATTTGAATGG CTTCCAGGAGCTCCAAACTG 57°C
SCD CGAGCCGGAGTTTACAGAAG TATTTCCTCAGCCCCCTTTT 57°C
UCP2 TCTTTCCCCACCTCTTCCTT AGGACGAAGATTCTGGCTGA 57°C
GSTO1 AGGACGCGTCTAGTCCTGAA TTCCCTGGGTATGCTTCATC 57°C
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Table 2 Genes down regulated by 0.25 µmol/l OTA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Affy_ID Gene title Abbreviation Gene function
202410_x_at insulin-like growth factor 2 (somatomedin a) IGF2  growth-promoting activity
210175_at chromosome 2 open reading frame 3 C2orf3  represses transcription
207401_at prospero-related homeobox 1 PROX1 may play a fundamental role in early development of CNS
208998_at uncoupling protein 2 (mitochondrial, proton carrier) UCP2
mitochondrial transporter protein that creates proton 
leaks across the inner mitochondrial membrane
215918_s_at spectrin, beta, non-erythrocytic 1 SPTBN1
tetrameric cytoskeletal protein essential for 
determination of cell shape, positioning of 
transmembrane proteins, and organization of 
organelles and molecular traffic
212877_at kinesin 2 KNS2 microtubule-associated force-producing protein that 
may play a role in organelle transport
208194_s_at signal transducing adaptor molecule (sh3 domain and itam motif) 2 STAM2
involved in intracellular signal transduction mediated 
by cytokines and growth factors.
215629_s_at deleted in lymphocytic leukemia, 2 DLEU2 may act as a tumor suppressor
204713_s_at coagulation factor v (proaccelerin, labile factor) F5
encodes coagulation factor V which is an essential 
factor of the blood coagulation cascade
222120_at hypothetical protein mgc13138 MGC13138 unknown
206348_s_at pyruvate dehydrogenase kinase, isozyme 3 PDK3
inhibits the mitochondrial pyruvate dehydrogenase, 
thus contributing to the regulation of glucose 
metabolism
209817_at
protein phosphatase 3 (formerly 2b), 
catalytic subunit, beta isoform 
(calcineurin a beta)
PPP3CB
belongs to the PPP phosphatase family, plays an 
important role in immune response, inhibitors of 
calcineurin can cause nephrotoxicity
205594_at zinc finger protein 652 ZNF652 transcription / cell division and chromosome partitioning
-2.0
-2.0
-2.3
-2.2
-2.1
-2.1
-2.5
-2.5
-2.4
-2.4
OTA                                            
0.25 µmol/l   
-3.9
-2.7
-2.6
fold change at 
24 h
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Table 3 Genes with FC ≥ -5 in response to 2.5 µmol/l OTA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Affy_ID Gene title Abbreviation Gene function
218325_s_at death inducer-obliterator 1 DIDO1 is thought to be involved in apoptosis and regulation of 
chromatin-based processes
217861_s_at prolactin regulatory element binding PREB binds to the prolactin promotor, may act as a transcriptional regulator
209817_at protein phosphatase 3 (formerly 2b), catalytic 
subunit, beta isoform (calcineurin a beta) PPP3CB
subunit of calcineurin, regulation of immune response, 
inhibitors of calcineurin induce nephrotoxicity
53076_at xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 (galactosyltransferase i) B4GALT7
belongs to type II membrane-bound glycoproteins that 
appear to have exclusive specificity for the donor 
substrate UDP-galactose
202492_at, 
203192_at
atp-binding cassette, sub-family b (mdr/tap), 
member 6 ABCB6
encodes for a membrane-associated protein, member 
of the superfamily of ATP-binding cassette (ABC) 
transporters, plays a role in mitochondrial function
203123_s_at solute carrier family 11 (proton-coupled divalent 
metal ion transporters), member 2 SLC11A2
encodes for a divalent metal transporter (DMT1), 
which carries iron, manganese, cobalt, nickel, 
cadmium, lead, copper, and zinc
222369_at hypothetical protein flj13848 −−− unknown
202257_s_at cd2 antigen (cytoplasmic tail) binding protein 2 CD2BP2 binds the cytoplasmic domain of CD2 through the GYF domain
218556_at orm1-like 2 (s. cerevisiae) ORMDL2 belongs to the ORM family, encodes for a membrane protein, widely expressed
218439_s_at comm domain containing 10 COMMD10 unknown -5.1
-12.4
-7.8
-7.6
-5.9
-5.9
-5.7
-5.5
-5.5
fold change at 
24 h
OTA                                            
2.5 µmol/l   
-5.3
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Table 4 Genes of carbohydrate metabolism down regulated in response to OTA treatment (24 h, 2.5 
µmol/l) in HepG2 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fold change 
at 24 h
Affy_ID Gene title Abbreviation Gene function OTA                                            2.5 µmol/l   
53076_at xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 (galactosyltransferase i) B4GALT7
one of seven beta-1,4-galactosyltransferase genes,  
potential targets for the control of cell growth and 
apoptosis, inflammation and infections
-5.9
219015_s_at glycosyltransferase 28 domain containing 1 ALG13 involved in N-linked glycosylation, important for glycoprotein folding and stability -4.9
211885_x_at fucosyltransferase 6 (alpha (1,3) fucosyltransferase) FUT6
essential for peripheral fucosylation of acute phase 
proteins -3.4
202847_at phosphoenolpyruvate carboxykinase 2 (mitochondrial) PCK2
mitochondrial enzyme that catalyzes the conversion of 
oxaloacetate to phosphoenolpyruvate, may be involved 
in gluconeogenesis in liver
-2.6
209208_at mannose-p-dolichol utilization defect 1 MPDU1
functions in synthesis of lipid-linked oligosaccharides 
(LLOs), important for protein folding and membrane 
anchoring
-2.6
202471_s_at isocitrate dehydrogenase 3 (NAD+) gamma IDH3G catalyzes rate-limiting step of the tricarboxylic acid 
cycle -2.5
204053_x_at phosphatase and tensin homolog (mutated in 
multiple advanced cancers 1) PTEN
functions as a tumor suppressor by negatively 
regulating AKT/PKB signaling pathway -2.4
201102_s_at, 
211065_x_at phosphofructokinase, liver PFKL
catalyzes a key step in glycolysis, namely the 
conversion of D-fructose 6-phosphate to D-fructose 1,6-
bisphosphate
-2.3
210820_x_at coenzyme q7 homolog, ubiquinone (yeast) COQ7 involved in ubiquinone biosynthesis -2.2
201509_at, 210418_s_at, 
210014_x_at isocitrate dehydrogenase 3 (NAD+) beta IDH3B
catalyzes rate-limiting step of the tricarboxylic acid 
cycle -2.1
202944_at n-acetylgalactosaminidase, alpha- NAGA
encodes the lysosomal enzyme alpha-N-
acetylgalactosaminidase, which cleaves alpha-N-
acetylgalactosaminyl moieties from glycoconjugates
-2.0
200738_s_at phosphoglycerate kinase 1 PGK1 glycolytic enzyme that catalyzes the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate -2.0
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Table 5a Genes of lipid metabolism down regulated in response to OTA treatment (24 h, 2.5 µmol/l) 
in HepG2 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fold change at 
24 h
Affy_ID Gene title Abbreviation Gene function OTA                                            2.5 µmol/l   
219015_s_at glycosyltransferase 28 domain containing 1 ALG13 involved in N-linked glycosylation, important for glycoprotein folding and stability -4.9
208964_s_at fatty acid desaturase 1 FADS1
member of the fatty acid desaturase (FADS) 
gene family. Desaturase enzymes regulate 
unsaturation of fatty acids through the 
introduction of double bonds between defined 
carbons of the fatty acyl chain
-4.0
220041_at phosphatidylinositol glycan, class z PIGZ
this gene encodes a protein that is localized to 
the endoplasmic reticulum, and is involved in 
GPI anchor biosynthesis
-3.5
221142_s_at peroxisomal trans-2-enoyl-coa reductase PECR key enzyme for a proposed peroxisomal chain 
elongation of fatty acids -3.5
202883_s_at, 
202884_s_at
protein phosphatase 2 (formerly 2a), regulatory 
subunit a (pr 65), beta isoform PPP2R1B
protein phosphatase 2 is one of the four major 
Ser/Thr phosphatases, and it is implicated in the 
negative control of cell growth and division
-3.4
209160_at aldo-keto reductase family 1, member c3 (3-
alpha hydroxysteroid dehydrogenase, type ii) AKR1C3
member of the aldo/keto reductase superfamily, 
these enzymes catalyze the conversion of 
aldehydes and ketones to their corresponding 
alcohols by utilizing NADH and/or NADPH as 
cofactors
-3.4
209546_s_at apolipoprotein l, 1 APOL1
apolipoprotein A-I is a relatively abundant 
plasma protein and is the major apoprotein of 
HDL. It is involved in the formation of most 
cholesteryl esters in plasma and also promotes 
efflux of cholesterol from cells
-3.4
204151_x_at, 
216594_x_at
aldo-keto reductase family 1, member c1 
(dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-
hydroxysteroid dehydrogenase)
AKR1C1
member of the aldo/keto reductase superfamily, 
these enzymes catalyze the conversion of 
aldehydes and ketones to their corresponding 
alcohols by utilizing NADH and/or NADPH as 
cofactors
-2.7
211423_s_at sterol-c5-desaturase (erg3 delta-5-desaturase homolog, fungal)-like SC5DL
this gene encodes an enzyme of cholesterol 
biosynthesis. The encoded protein catalyzes the 
conversion of lathosterol into 7-
dehydrocholesterol
-2.7
202025_x_at acetyl-coenzyme a acyltransferase 1 (peroxisomal 3-oxoacyl-coenzyme a thiolase) ACAA1
acetyl-Coenzyme A acyltransferase (ACAA1) is 
an enzyme operative in the beta-oxidation 
system of the peroxisomes
-2.6
219238_at, 51146_at
phosphatidylinositol glycan, class v, official full 
name: phosphatidylinositol glycan anchor 
biosynthesis, class V
PIGV
glycosylphosphatidylinositol (GPI) is a complex 
glycolipid that anchors many proteins to the cell 
surface. PIGV adds the second mannose to the 
GPI core
-2.6
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Table 5b Genes of lipid metabolism down regulated in response to OTA treatment (24 h, 2.5 
µmol/l) in HepG2 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fold change at 
24 h
Affy_ID Gene title Abbreviation Gene function OTA                                            2.5 µmol/l   
209699_x_at
aldo-keto reductase family 1, member c2 
(dihydrodiol dehydrogenase 2; bile acid binding 
protein; 3-alpha hydroxysteroid dehydrogenase, 
type iii)
AKR1C2
member of the aldo/keto reductase superfamily, 
These enzymes catalyze the conversion of 
aldehydes and ketones to their corresponding 
alcohols by utilizing NADH and/or NADPH as 
cofactors
-2.5
209759_s_at dodecenoyl-coenzyme a delta isomerase (3,2 trans-enoyl-coenzyme a isomerase) DCI
this gene encodes a member of the 
hydratase/isomerase superfamily. The protein 
encoded is a key mitochondrial enzyme involved 
in beta-oxidation of unsaturated fatty acids
-2.4
201885_s_at cytochrome b5 reductase 3 CYB5R3
functions in desaturation and elongation of fatty 
acids, in cholesterol biosynthesis, and in drug 
metabolism
-2.4
209509_s_at
dolichyl-phosphate (udp-n-acetylglucosamine) n-
acetylglucosaminephosphotransferase 1 (glcnac-
1-p transferase)
DPAGT1
the protein encoded by this gene is an enzyme 
that catalyzes the first step in the dolichol-linked 
oligosaccharide pathway for glycoprotein 
biosynthesis.
-2.4
204053_x_at phosphatase and tensin homolog (mutated in 
multiple advanced cancers 1) PTEN
functions as a tumor suppressor by negatively 
regulating AKT/PKB signaling pathway -2.4
201790_s_at 7-dehydrocholesterol reductase DHCR7
the DHCR7 gene encodes delta-7-sterol 
reductase, the enzyme of mammalian sterol 
biosynthesis that converts 7-dehydrocholesterol 
(7-DHC) to cholesterol
-2.3
212393_at, 39835_at set binding factor 1 SBF1 (MTMR5)
cellular function of MTMR5 is unknown, but male 
mice deficient for MTMR5 are infertile -2.2
209122_at adipose differentiation-related protein ADFP
adipocyte differentiation-related protein is 
associated with the globule surface membrane 
material. This protein is a major constituent of 
the globule surface
-2.2
211708_s_at, 
200831_s_at stearoyl-coa desaturase (delta-9-desaturase) SCD
converts saturated fatty acids (SFAs) into 
monounsaturated fatty acids (MUFAs) -2.1
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Table 6 Genes of cell cycle and cell proliferation down regulated in response to OTA treatment (24 
h, OTA 2.5 µmol/l) in HepG2 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fold change 
at 24 h
Affy_ID Gene title Abbreviation Gene function OTA                                            2.5 µmol/l   
205302_at insulin-like growth factor binding protein 1 IGFBP1 binds both insulin-like growth factors (IGFs) I and II, pro-survival function in liver -4.2
202883_s_at, 202884_s_at protein phosphatase 2 (formerly 2a), 
regulatory subunit a (pr 65), beta isoform PPP2R1B
subunit of protein phosphatase 2, implicated 
in the negative control of cell growth and 
division
-3.4
208601_s_at tubulin, beta 1 TUBB1
one of six isotypes of beta tubulin that forms 
as heterodimer with alpha tubulin the 
microtubule in mammals
-3.4
203558_at cullin 7 CUL7 inhibitor of Myc-induced apoptosis -3.3
205436_s_at h2a histone family, member x H2AFX
belongs to the family of histones, that are 
basic nuclear proteins responsible for the 
nucleosome structure of the chromosomal 
fiber in eukaryotes
-2.8
200712_s_at, 200713_s_at microtubule-associated protein, rp/eb family, 
member 1 MAPRE1
during mitosis, the protein is associated with 
the centrosomes and spindle microtubules -2.8
201469_s_at shc (src homology 2 domain containing) transforming protein 1 SHC1
longevity-associated gene, might be 
involved in regulating mitochondrial 
metabolism
-2.8
202642_s_at transformation/transcription domain-
associated protein TRRAP involved in chromatin based processes -2.6
220386_s_at echinoderm microtubule associated protein like 4 EML4 essential for microtubule formation -2.5
204053_x_at phosphatase and tensin homolog (mutated in 
multiple advanced cancers 1) PTEN
functions as a tumor suppressor by 
negatively regulating AKT/PKB signaling 
pathway.
-2.4
216870_x_at deleted in lymphocytic leukemia, 2 DLEU2 may act as a tumor suppressor -2.3
208796_s_at cyclin g1 CCND1
functions as a regulatory subunit of CDK4 or 
CDK6, whose activity is required for cell 
cycle G1/S transition
-2.2
212099_at ras homolog gene family, member b RHOB
regulates endosome transport by promoting 
actin assembly on endosomal membranes 
through Dia1
-2.1
217301_x_at retinoblastoma binding protein 4 RBBP4 involved in histone acetylation and 
chromatin assembly -2.1
209817_at protein phosphatase 3 (formerly 2b), catalytic 
subunit, beta isoform (calcineurin a beta) PPP3CB
belongs to the PPP phosphatase family, 
plays an important role in immune 
response, inhibitors of calcineurin can 
cause nephrotoxicity
-2.0
200020_at tar dna binding protein TARDBP transcriptional repressor -2.0
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Table 7 Genes involved in calcium homeostasis down regulated in response to OTA treatment 
 (24 h, OTA 2.5 µmol/l) in HepG2 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fold change at 
24 h
Affy_ID Gene title Abbreviation Gene function OTA                                            2.5 µmol/l   
210390_s_at chemokine (c-c motif) ligand 14 CCL14 one of several CC cytokine genes, induces 
changes in intracellular calcium concentration -2.6
209771_x_at, 216379_x_at, 
266_s_at, 209772_s_at
cd24 antigen (small cell lung carcinoma 
cluster 4 antigen) CD24
cell surface glycoprotein, involved in cell 
adhesion and signalling -2.6
209186_at atpase, ca++ transporting, cardiac 
muscle, slow twitch 2 ATP2A2
encodes one of the SERCA Ca(2+)-ATPases, 
which are intracellular Ca (2+) pumps located in 
the sarcoplasmic or endoplasmic reticula
-2.3
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Figure 1. Chemical structure of ochratoxin A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Classification by fold change of down regulated HepG2 genes after 24 h treatment with 
2.5 µmol/l OTA (dchip, p ≤ 0.05). 
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Figure 3. Classification of mitochondrial proteins encoded by down regulated genes in HepG2 cells 
after 24 h treatment with 2.5 µmol/l OTA (dchip, p ≤ 0.05, DAVID functional clustering). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Classification of cytoskeleton proteins encoded by down regulated genes in HepG2 cells 
after 24 h treatment with 2.5 µmol/l OTA (dchip, p ≤ 0.05, DAVID functional clustering). 
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Figure 5. Classification by function of at least twofold down regulated genes in HepG2 cells after 24 
h treatment with 2.5 µmol/l OTA (dchip, p ≤ 0.05, DAVID functional clustering). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Classification by localization of at least twofold down regulated genes in HepG2 cells 
after 24 h treatment with 2.5 µmol/l OTA (dchip, p ≤ 0.05, DAVID functional clustering). 
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Figure 7. Verification of gene expression changes in HepG2 cells following ochratoxin A treatment 
(2.5 µmol/l, 24h) as indicated by microarray data. Expression of selected target genes was 
determined via quantitative real-time PCR as an independent method. Data of real-time PCR are mean 
values with SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Western Blot analysis: Down regulation of IGFBP1 (A) and GSTO1 (B) by 48 h treatment of 
HepG2 cells with 2.5 µmol/l OTA. One representative out of three experiments is shown. 
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Figure 9. (A) Representative original tracings showing the Fura-2 fluorescence ratios (340/380 
nm) - indicating intracellular Ca2+ concentration - in control (upper line) and OTA-treated (lower line, 
2.5 µmol/l for 24 h) HepG2 cells. 
 
Where indicated, thapsigargin (1 µmol/l) was added to Ca2+-free bath solution, resulting in a release 
of Ca2+ from intracellular stores (peak 1). Readdition of extracellular Ca2+ in the presence of 
thapsigargin led to an influx of extracellular Ca2+ (peak 2). 
 
(B) refers to peak 2: Changes in Fura-2 fluorescence ratios (340/380 nm) for control (n=7) and OTA-
treated (n=9) HepG2 cells in the presence of thapsigargin. Data are mean values with SEM (p ≤ 0.05). 
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General Discussion 
The mycotoxin ochratoxin A (OTA) has been shown to exhibit a wide range of toxic effects 
including nephro- and hepatotoxicity in animals [1]. Furthermore, OTA has been classified as 
a possible human carcinogen by the International Agency for Research on Cancer (IARC) 
[2]. The toxicity mechanisms of OTA are still incompletely understood. Numerous in vitro and 
in vivo studies indicate that the generation of reactive oxygen species (ROS) may play a 
pivotal role in OTA toxicity. In fact, OTA has been shown to enhance NADPH and ascorbate-
mediated lipid peroxidation in rat liver microsomes [3]. In monkey kidney cells (Vero cells), a 
concentration dependent induction in the formation of malondialdehyde (MDA), a biomarker 
of lipid peroxidation, was observed in response to OTA treatment [4].  In Wistar rats, OTA 
injection enhanced ethane exhalation, which is again indicative of an increase in lipid 
peroxidation [3]. Furthermore, there is increasing experimental evidence of OTA induced 
DNA damage [5] and protein oxidation [6].  
 
Several studies aimed to counteract OTA induced oxidative stress by inducing antioxidant 
enzymes such as superoxide dismutase (SOD) and catalase [3, 7]. A broad range of 
antioxidants, including lipophilic synthetic antioxidants like butylated hydroxytoluene (BHT) 
[3], natural fat-soluble antioxidants such as vitamin E [8-10], hydrophilic antioxidants like 
vitamin C [8, 11], and also the hormone melatonin [12], have been tested for their potntial to 
diminish OTA mediated oxidative damage in cultured cells and in rodents. As far as 
polyphenols are concerned, one study used berry and leaf juice of the common grape Vitis 
vinifera to counteract OTA toxicity in mice [13]. 
Although the above mentioned studies indicate a potential for the tested antioxidants to 
counteract OTA toxicity, their efficacy may depend on various factors including: duration of 
OTA treatment, concentrations of the tested antioxidants, molar ratio between OTA and the 
test compound, concentration of serum in the cell culture medium, and cell type, to name a 
few. Furthermore, the way the antioxidant is administered may be an important determinant 
of its efficacy to counteract OTA toxicity. BHT, for example, abolished the OTA enhanced 
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lipid peroxidation in rat liver microsomes while SOD and catalase had no effect [3]. In 
contrast, when injected subcutaneously in rats, SOD and catalase prevented most of the 
nephrotoxic effects induced by OTA [7]. Similarly, α-tocopherol counteracted the OTA 
induced loss of cell viability in bovine mammary epithelia (BME-UV1) cells by about 10% [9], 
but did not protect LLC-PK1 kidney cells from OTA induced cell death [10], although a 
significant decrease in ROS levels was observed. Vitamin C exhibited no effect on MDA 
production in chickens fed an OTA containing diet [8], but significantly minimized the 
incidence of abnormalities in mitotic and meiotic chromosomes observed in mice when 
administered OTA orally for 45 days [11]. The application of juice of the grape Vitis vinifera 
partly protected from OTA induced hepatorenal carcinoma [13], but the active principle 
accounting for this protection was not identified.  
 
Summarising the evidence from the above cited studies, it remained unclear, which 
antioxidants might be most potent in counteracting OTA induced cytotoxicity and biomarkers 
of oxidative stress. Therefore, we studied the potency of selected antioxidants to counteract 
OTA induced cell death. As cell death in general represents the endpoint of toxicity, a 
decrease in OTA induced cell death by antioxidants would be an indication of their 
effectiveness in counteracting OTA toxicity. Since the liver is one of the main targets for OTA 
and studies concerning the effects of antioxidants in OTA treated liver cells are rare, we 
performed our experiments in the human hepatoma derived cell line HepG2, which 
represents a frequently used human model for biotransformation and cytotoxicity [14, 15]. 
Furthermore, we regarded HepG2 cells as especially suitable for our studies, because they 
are rich in mitochondria [16] and thus relatively potent producers of ROS. We studied the 
antioxidant vitamin α-tocopherol and the dietary flavonoids EGCG, CAT, EC, GEN, DAI, 
EQU, and QUE for their abilities to protect liver cells from OTA induced cytotoxicity, because 
so far little information is available regarding the role of flavonoids in counteracting OTA 
toxicity. 
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At first we determined the in vitro antioxidative capacities of the flavonoids using the FRAP, 
DPPH, and TEAC assays. While the DPPH and TEAC assays are based on the ability of a 
compound to scavenge coloured radicals converting them into colourless products [17], the 
FRAP assay basically measures the ferric reducing ability of an antioxidant [18]. Remarkably, 
all three assays revealed similar antioxidative capacities for the flavonoids, in the order 
EGCG > QUE > CAT/EC > GEN/DAI/EQU. However, neither pre-treatment with α-tocopherol 
(48 h, 100 µmol/l) nor flavonoids (48 h, 50 µmol/l) increased the viability of OTA treated 
(48 h, 20 µmol/) HepG2 cells which was approximately 65% compared to untreated cells as 
determined by the neutral red assay [19]. Furthermore, we observed that pre-incubation with 
α-tocopheryl phosphate (α-TOC-P) and quercetin (QUE) even enhanced OTA toxicity in a 
dose dependent manner.  
  
There may be several reasons why antioxidants do not protect from OTA toxicity in HepG2 
cells: 1. Oxidative stress might not play a pivotal role in OTA induced cytotoxicity in HepG2 
cells, 2. The uptake of the antioxidants into HepG2 cells might not be sufficient, 3. The 
antioxidants might be rapidly metabolised in HepG2 cells, 4. The uptake into the cytosol 
might be sufficient but the antioxidants might not reach the relevant sites of free radical 
generation such as the inner mitochondrial membrane.  
 
It has been previously shown that an overnight incubation with 1-30 µmol/l α-tocopherol 
attenuated lipid peroxidation in HepG2 cells [20]. However, we found that a 48 h pre-
treatment with 100 µmol/l α-tocopherol, which is a concentration more than twice the upper 
range in human plasma (15- 40 µmol/l) [21], did not prevent from OTA induced cell death in 
HepG2 cells. Similarly, Schaaf and co-workers observed a significant decrease of ROS 
production in LLC-PK1 cells incubated with α-tocopherol, but no protection against OTA 
induced cytotoxicity. The authors concluded that lipid peroxidation might not be centrally 
involved in OTA toxicity in LLC-PK1 cells. Furthermore, as it has also been demonstrated 
that OTA inhibits site I and II mitochondrial respiration in proximal tubular cells [22], Schaaf 
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and co-workers hypothesized that mitochondrial dysfunction might be the main cause for 
OTA induced cytotoxicity in LLC-PK1 cells. The lack of protection of α-tocopherol against 
OTA cytotoxicity and the massive down regulation of mitochondrial genes observed in our 
studies in HepG2 cells (Chapter six) support the hypothesis that an impairment of 
mitochondrial function is more likely to cause OTA toxicity in cultured hepatocytes than lipid 
peroxidation.  
 
Our finding that α-TOC-P and QUE even increased OTA toxicity in a dose dependent 
manner may possibly be due to their effects on glutathione-S-transferases (GSTs). GSTs are 
a family of enzymes that catalyze the conjugation of glutathione (GSH) to electrophiles 
forming more polar glutathione-S-conjugates which are then eliminated via urine [23]. Thus, 
GSTs play a crucial role in detoxifying endobiotic and xenobiotic compounds; they also have 
been linked to OTA detoxification [24, 25]. Six GST classes have been described to date: 
GST-A, -M, -P, -T, -Z, and -O [26]. GSTO with its members GSTO1 and GSTO2 represents a 
relatively new class of GSTs which were characterized by Board and co-workers in 2000 
[27]. Unlike other GSTs GSTO has thiol transferase and dehydroascorbate reductase activity 
and is therefore associated with the cellular response to oxidative stress [27]. Recently it has 
been demonstrated that α-TOC-P inhibits the activity of GSTO1 in a concentration dependent 
manner [28]. Similarly, it has been reported that QUE decreases GST activity [29]. Since our 
results demonstrated that OTA decreased GSTO1 mRNA and protein levels in HepG2 cells 
(Chapter five), we suggest that the synergistic toxic effects of α-TOC-P / OTA and CAT / 
OTA, respectively, are due to a simultaneous inhibition of GSTs by both OTA as well as 
α-TOC-P and CAT, respectively.  
 
In addition to investigating the possible protective role of antioxidants in OTA induced 
cytotoxicity, we tested the impact of OTA on gene expression in liver cells. To this end, we 
performed a large-scale gene expression profile of OTA treated HepG2 cells using Affymetrix 
GeneChip® technology. Out of 14500 genes represented on the microarray, 13 and 250 
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genes were down regulated in HepgG2 cells incubated with 0.25 and 2.5 µmol/l OTA, 
respectively. Decreased mRNA levels of calcineurin A beta (PPP3CB) which regulates 
inflammatory signalling pathways in immune cells [30, 31] and of the uncoupling protein 2 
(UCP2), which has been suggested to control the production of reactive oxygen species 
(ROS) [32], were observed in response to 0.25 µmol/l OTA. In addition, numerous genes 
encoding for proteins involved in energy and xenobiotics metabolism showed an at least 
twofold down regulation due to incubation with 2.5 µmol/l OTA. For example, two genes 
encoding for key enzymes in glycolysis, namely phosphofructokinase (PFK) and 
phosphoglycerate kinase 1 (PGK1), which catalyze the conversion of D-fructose 6-phosphate 
to D-fructose 1,6-bisphosphate and 1,3-diphosphoglycerate to 3-phosphoglycerate, 
respectively, were both twofold down regulated. mRNA levels of critical genes for 
mitochondrial function, mainly encoding for oxidoreductases such as isocitrate 
dehydrogenase 3 (NAD+) beta (IDH3B), which belongs to the NAD (+)-dependent isocitrate 
dehydrogenases which catalyze the allosterically regulated rate-limiting step of the 
tricarboxylic acid cycle, were significantly lowered by OTA. Overall, our results indicate that 
OTA might lead to ATP depletion in HepG2 cells via down regulation of important genes 
involved in carbohydrate metabolism and mitochondrial function.  
 
We further observed that OTA decreased the insulin-like growth factor binding protein 1 
(IGFBP1), both at the mRNA and protein level. IGFBP1 is one of six members of the family 
of IGFBPs (IGFBP1-6) which belong to the so-called “IGF axis”, a complex system consisting 
of two cell-surface receptors (IGF1R and IGF2R), two ligands (IGF1 and IGF2), six high-
affinity IGF binding proteins (IGFBPs), as well as associated IGFBP degrading enzymes. The 
IGF “axis” has been shown to play an important role in the promotion of cell proliferation and 
the inhibition of cell death [33]. Interestingly, IGFBP1 has recently been demonstrated to 
exhibit an important intracellular function that is independent of the interactions with the 
IGFs: Leu and co-workers found in HepG2 cells that IGFBP1 is a pro-survival factor that 
binds to the “BCL2-antagonist/killer” (BAK) and antagonizes the pro-apoptotic actions of the 
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nuclear transcription factor p53 in mitochondria [34]. Moreover, IGFBP1 production in HepG2 
cells has been reported to be influenced by ROS [35]. Therefore our finding that OTA lowers 
both mRNA and protein levels of IGFBP1 in HepG2 cells indicates that IGFBP1 might be an 
important factor in OTA induced liver cytotoxicity with mitochondria being a major target of 
OTA.  
 
Taken together, the results of our studies show that down regulation of key genes of the 
cellular hepatic metabolism, including PGK1, UCP2, IDH3B, IGFBP1 and GSTO1, seem to 
play a critical role in OTA induced liver toxicity. Our hypothesis that the inhibition of 
mitochondrial function is the pivotal event in OTA toxicity is underlined by our finding that all 
analyzed mitochondrial genes in HepG2 cells were strongly down regulated. Our observation 
that antioxidants were not able to protect HepG2 cells from OTA-induced cytotoxicity does 
not fully exclude an involvement of ROS in OTA toxicity, which may also be due - to a certain 
extent - to insufficient concentrations of the antioxidants at the relevant sites of cellular ROS 
generation, such as mitochondria. Systematic studies on the distribution of OTA in specific 
subcellular compartments may contribute to a better understanding of OTA mediated toxicity. 
Our data suggest that one approach to counteract OTA cytotoxicity may be the use of 
mitochondria-targeted antioxidants. Finally, studies in rodents are warranted to test if and to 
what extent changes in gene expression observed in HepG2 cells apply to the situation in 
vivo.  
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APPENDIX
Table A1  Cytotoxicity of OTA in HepG2 liver cells after 24, 48 and 72 h incubation with 2.5 –
100 µmol/l OTA
Viability %
OTA (µmol/l) V1 V2 V3 V4 MW STABW
2,5 96,3 104,6 117,4 99,0 104,3 9,4 9,0
5 92,7 96,0 106,4 91,5 96,7 6,8 7,0
10 73,3 83,9 83,8 83,9 81,2 5,3 6,5
20 23,5 72,9 63,4 77,3 71,2 7,1 10,0
50 67,9 51,4 54,2 77,9 62,9 12,4 19,7
100 63,1 48,4 47,3 75,2 58,5 13,3 22,7
48 h:
Viability %
OTA (µmol/l) V1 V2 V3 V4 MW STABW
2,5 99,8 99,1 102,3 99,5 100,2 1,4 1,4
5 88,3 77,9 98,9 82,1 86,8 9,1 10,5
10 79,2 67,0 82,9 60,9 72,5 10,3 14,2
20 56,5 54,9 51,3 42,5 51,3 6,3 12,2
50 53,0 43,6 37,5 30,1 41,1 9,7 23,6
100 46,0 39,8 32,5 25,3 35,9 9,0 25,0
72 h:
Viability %
OTA (µmol/l) V3 V4 V5 V5 MW STABW
2,5 98,7 93,2 87,5 89,3 92,2 5,0 5,4
5 86,9 76,4 70,8 73,8 77,0 7,0 9,1
10 74,0 44,3 49,1 50,4 54,5 13,3 24,4
20 45,0 22,7 37,4 38,9 36,0 9,5 26,3
50 19,4 12,4 25,5 29,2 21,6 7,4 34,0
100 16,3 11,2 26,1 27,2 20,2 7,7 38,3
coefficient 
of variation 
(%)
coefficient 
of variation 
(%)
coefficient 
of variation 
(%)
Table A2   FRAP (ferric reducing ability of plasma) test  of selected flavonoids
Table A3  TEAC (trolox equivalent antioxidant capacity) test of selected flavonoids
Flavonoid c( µmol/l)
Absorption 593nm
1 2 3 m STABW VK (%)
Quercetin 200 0,852 0,926 0,999 0,926 0,074 7,90 619,0100 0,475 0,471 0,485 0,477 0,007 1,47 319,7
EGCG 200 0,843 0,922 0,903 0,889 0,041 4,61 594,3100 0,593 0,633 0,636 0,621 0,024 3,86 415,7
Catechin 200 0,342 0,337 0,386 0,355 0,027 7,61 259,0100 0,170 0,187 0,167 0,175 0,011 6,29 118,3
Epicatechin 200 0,340 0,348 0,386 0,358 0,025 6,98 240,3100 0,182 0,190 0,177 0,183 0,007 3,83 123,7
Genistein 200 0,024 0,012 0,018 0,018 0,006 33,30 13,7100 0,005 0,004 0,007 0,005 0,002 40,00 5,0
Equol 200 0,031 0,026 0,026 0,028 0,003 10,71 20,3100 0,024 0,021 0,021 0,022 0,002 9,09 16,3
** aae= ascorbic acid equivalents
FRAP-values   
  (µmol/l 
aae**)
A
Absorption (734 nm)
Flavonoid 1 2 3 m STABW VK (%) TEAC-values
BW (ABTS-Rad.Lsg.) 0,724 0,728 0,724 0,725 0,002 0,318
Trolox (2,5 µM) 0,639 0,629 0,632 0,633 0,005 0,810 12,7 1,0
Quercetin (2,5 µM) 0,469 0,471 0,465 0,468 0,003 0,652 35,4 2,8
EGCG (2,5 µM) 0,351 0,367 0,357 0,358 0,008 2,256 50,6 4,0
Catechin (2,5 µM) 0,498 0,508 0,506 0,504 0,005 1,050 30,5 2,4
Epicatechin (2,5 µM) 0,495 0,468 0,492 0,485 0,015 3,051 33,1 2,6
Genistein (2,5 µM) 0,607 0,629 0,613 0,616 0,011 1,845 15,0 1,2
Equol (2,5 µM) 0,561 0,553 0,558 0,557 0,004 0,725 23,2 1,8
B
Absorption (734 nm)
Flavonoid 1 2 3 m STABW VK (%) TEAC-values
BW (ABTS-Rad.Lsg.) 0,730 0,716 0,727 0,724 0,007 1,018
Trolox (2,5 µM) 0,635 0,626 0,639 0,633 0,007 1,051 12,6 1,0
Quercetin (2,5 µM) 0,345 0,358 0,348 0,350 0,007 1,943 38,8 3,1
EGCG (2,5 µM) 0,470 0,427 0,433 0,443 0,023 5,253 51,7 4,1
Catechin (2,5 µM) 0,500 0,470 0,515 0,495 0,023 4,629 31,6 2,5
Epicatechin (2,5 µM) 0,486 0,466 0,488 0,480 0,012 2,534 33,7 2,7
Genistein (2,5 µM) 0,649 0,648 0,665 0,654 0,010 1,459 9,7 0,8
Equol (2,5 µM) 0,557 0,545 0,557 0,553 0,007 1,253 23,6 1,8
Reduction of   
 Absorption 
% 
Reduction of   
 Absorption 
% 
Table A4  Viability of HepG2 cells after preincubation with Vitamin E (VE) or flavonoids        
followed by OTA treatment (20  µM, 48 h) 
test compound
Viability %
STABW
1 2 3 m
control 1 62,1 65,7 64,7 64,2 1,9
control 2 67,2 73,2 70 70,1 3,0
200 µM (48h) 67 67,3 66,2 66,8 0,6
VE 100 µM (48h) 58,8 62,9 54,4 58,7 4,3
VE 200 µM (6h) 65,3 73,7 73,9 71,0 4,9
VE 100 µM (6h) 76,9 73,2 76,7 75,6 2,1
EGCG 100 µM (48h) 66,4 69 68,3 67,9 1,3
EGCG 50 µM(48h) 72,5 68,9 75,1 72,2 3,1
Quercetin 100 µM (48h) 69,2 64,8 69,2 67,7 2,5
Quercetin 50 µM (48h) 65,4 64,3 65,2 65,0 0,6
Genistein 50 µM (48h) 66,7 66,3 67,6 66,9 0,7
Table A5  Influence of foetal calf serum concentration (FCS) on the viability 
of HepG2 cells after 24 h incubation with Ochratoxin A (OTA) 
1. FCS 10 %
viability (%)
OTA (µM) m1 m2 m3 MW STABW VC (%)
0,0 100,0 100,0 100,0 100,0 0,0 0,0
0,25 101,7 104,4 104,9 103,7 1,7 1,7
0,5 108,8 103,6 111,6 108,0 4,1 3,8
1 108,6 102,3 109,5 106,8 3,9 3,7
5 93,0 89,2 97,2 93,1 4,0 4,3
15 78,1 78,2 80,3 78,9 1,2 1,6
25 65,0 62,0 69,3 65,4 3,7 5,6
50 59,3 65,3 63,4 62,7 3,1 4,9
2. FCS 5%
viability (%)
OTA (µM) m1 m2 m3 MW STABW VC (%)
0,0 100,0 100,0 100,0 100,0 0,0 0,0
0,25 96,4 96,9 101,7 98,3 2,9 3,0
0,5 104,3 95 102,2 100,5 4,9 4,9
1 98,0 105,1 100,0 101,0 3,7 3,6
5 79,4 72,3 82,0 77,9 5,0 6,4
15 61,3 53,3 61,6 58,7 4,7 8,0
25 54,2 46,8 58,1 53,0 5,7 10,8
50 55,9 52,0 46,9 51,6 4,5 8,7
3. FCS 2,5%
viability (%)
OTA (µM) m1 m2 m3 MW STABW VC (%)
0,0 100,0 100,0 100,0 100,0 0,0 0,0
0,25 107,1 108,6 114,2 110,0 3,7 3,4
0,5 97,5 93,1 99,4 96,7 3,2 3,3
1 86,9 93,1 89,5 89,8 3,1 3,5
5 64,9 60,3 68,9 64,7 4,3 6,7
15 52,8 54,1 53,3 53,4 0,7 1,2
25 53,7 49,2 52,8 51,9 2,4 4,6
50 46,4 49,3 52,6 49,4 3,1 6,3
4. FCS 0%
viability (%)
OTA (µM) m1 m2 m3 MW STABW VC (%)
0,0 100,0 100,0 100,0 100,0 0,0 0,0
0,25 50,4 50,2 45,9 48,8 2,5 5,2
0,5 50,6 45,8 48 48,1 2,4 5,0
1 46,3 47,2 45,9 46,5 0,7 1,4
5 51,5 48,4 47,9 49,3 2,0 4,0
15 40,5 44,1 41,8 42,1 1,8 4,3
25 37,6 43,8 43,1 41,5 3,4 8,2
50 41,3 36,7 35,1 37,7 3,2 8,5
Table A6  Cytotoxicity of ochratoxin A (24 h, 1 – 15 µmol/l) on HepG2 cells after pre-
                 incubation with N-acetylcysteine (NAC, 24 h, 0 – 4 mmol/l) 
OTA 1 µM 
NAC (mM) viability (%) m stabw vc (%) mortality (%) m stabw vc (%)
46,2 47,8 49,6 53,8 52,2 50,4
0 46,3 51,4 50,7 48,7 2,2 4,6 53,7 48,6 49,3 51,3 2,2 4,3
0,2 47,5 50,1 51,0 49,5 1,8 3,7 52,5 49,9 49,0 50,5 1,8 3,6
0,5 49,2 50,9 52,6 50,9 1,7 3,3 50,8 49,1 47,4 49,1 1,7 3,5
1 48,5 50,6 48,2 49,1 1,3 2,7 51,5 49,4 51,8 50,9 1,3 2,6
2 48,1 48,7 51,4 49,4 1,8 3,6 51,9 51,3 48,6 50,6 1,8 3,5
4 53 49,6 52 51,5 1,7 3,4 47 50,4 48 48,5 1,7 3,6
OTA 5 µM 
NAC (mM) viability (%) m stabw vc (%) mortality (%) m stabw vc (%)
44,7 46,4 43,1 55,3 53,6 56,9
0 45,2 47,2 44,2 45,1 1,5 3,3 54,8 52,8 55,8 54,9 1,5 2,7
0,2 48,0 48,2 46,4 47,5 1,0 2,1 52,0 51,8 53,6 52,5 1,0 1,9
0,5 44,8 47,4 47,6 46,6 1,6 3,4 55,2 52,6 52,4 53,4 1,6 2,9
1 35,4 46,5 43,6 41,8 5,8 13,8 64,6 53,5 56,4 58,2 5,8 9,9
2 44,2 46,6 41,5 44,1 2,6 5,8 55,8 53,4 58,5 55,9 2,6 4,6
4 43,9 44,5 46,5 45,0 1,4 3,0 56,1 55,5 53,5 55,0 1,4 2,5
OTA 15 µM 
NAC (mM) viability (%) m stabw vc (%) mortality (%) m stabw vc (%)
35,8 37,5 35,2 64,2 62,5 64,8
0 39,0 37,7 38,2 37,2 1,5 3,9 61,0 62,3 61,8 62,8 1,5 2,3
0,2 39,3 36,2 41,2 38,9 2,5 6,5 60,7 63,8 58,8 61,1 2,5 4,1
0,5 38,5 37,0 39,2 38,2 1,1 2,9 61,5 63,0 60,8 61,8 1,1 1,8
1 42,0 37,9 38,4 39,4 2,2 5,7 58,0 62,1 61,6 60,6 2,2 3,7
2 41,7 37,6 37,5 38,9 2,4 6,2 58,3 62,4 62,5 61,1 2,4 3,9
4 41,9 41,6 39,7 41,1 1,2 2,9 58,1 58,4 60,3 58,9 1,2 2,0
Table A7  Cytotoxicity of ochratoxin A (24 h, 1 – 15 µmol/l) on HepG2 cells after pre-
                 incubation with buthionine-sulfoximine (BSO, 24 h, 0 – 500 µmol/l)
OTA 1 µM 
BSO (µM) viability (%) m stabw vc (%) mortality (%) m stabw vc (%)
49,9 49,7 53,7 50,1 50,3 46,3
0 50,1 51,1 53,3 51,3 1,8 3,5 49,9 48,9 46,7 48,7 1,8 3,6
5 48,9 51,3 54,3 51,5 2,7 5,3 51,1 48,7 45,7 48,5 2,7 5,6
25 51,1 49,7 52,2 51,0 1,3 2,5 48,9 50,3 47,8 49,0 1,3 2,6
50 47,0 49,1 48,0 48,0 1,1 2,2 53,0 50,9 52,0 52,0 1,1 2,0
100 43,8 49 49,6 47,5 3,2 6,7 56,2 51 50,4 52,5 3,2 6,1
500 43,3 40,4 39,3 41,0 2,1 5,0 56,7 59,6 60,7 59,0 2,1 3,5
OTA 5 µM 
BSO (µM) viability (%) m stabw vc (%) mortality (%) m stabw vc (%)
48,7 48,9 48,0 51,3 51,1 52,0
0 45,6 49,7 50,8 48,6 1,8 3,6 54,4 50,3 49,2 51,4 1,8 3,4
5 49,3 51,5 49,9 50,2 1,1 2,3 50,7 48,5 50,1 49,8 1,1 2,3
25 47,0 47,4 49,4 47,9 1,3 2,7 53,0 52,6 50,6 52,1 1,3 2,5
50 40,9 41,5 45,5 42,6 2,5 5,9 59,1 58,5 54,5 57,4 2,5 4,4
100 41,2 44,8 45,3 43,8 2,2 5,1 58,8 55,2 54,7 56,2 2,2 4,0
500 41,2 40,0 36,9 39,4 2,2 5,6 58,8 60 63,1 60,6 2,2 3,7
OTA 15 µM 
BSO (µM) viability (%) m stabw vc (%) mortality (%) m stabw vc (%)
43,7 45,1 46,0 56,3 54,9 54,0
0 43,0 49,3 45,5 45,4 2,2 4,9 57,0 50,7 54,5 54,6 2,2 4,0
5 44,8 45,1 47,7 45,9 1,6 3,5 55,2 54,9 52,3 54,1 1,6 2,9
25 41,7 42,4 43,6 42,6 1,0 2,3 58,3 57,6 56,4 57,4 1,0 1,7
50 39,6 41,1 41,7 40,8 1,1 2,7 60,4 58,9 58,3 59,2 1,1 1,8
100 39,9 39,7 43,4 41,0 2,1 5,1 60,1 60,3 56,6 59,0 2,1 3,5
500 38 37,9 33,4 36,4 2,6 7,2 62 62,1 66,6 63,6 2,6 4,1
